T cells expressing chimeric antigen receptors

By designing CAR polypeptides that specifically bind CD79b and CD19, binding to hinge and signaling domains, the problem of CAR T cell therapy failure when target antigen is lost is solved, and the killing efficacy of B cell malignant tumors and negative CD19 is improved. Treatment effects of lymphoma recurrence.

CN110799640BActive Publication Date: 2024-11-12THE GENERAL HOSPITAL CORP +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201880040774.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-02-07
Filing Date
2018-06-07
Publication Date
2024-11-12
Estimated Expiration
2038-06-07

AI Technical Summary

Technical Problem

CAR T cell therapy fails when recognizing the missing target antigen, resulting in tumor escape. The prior art is difficult to effectively target CD19-negative lymphoma recurrence and other conditions.

Method used

Design chimeric antigen receptor (CAR) polypeptides containing extracellular domains that specifically bind to CD79b and CD19, binding to hinge, transmembrane and signaling domains, for targeting CD79b and CD19 antigens and enhancing T cell killing efficacy.

Benefits of technology

It improves the killing efficacy against targeted B-cell malignant tumors and reduces the risk of tumor escape, especially in the treatment effect of CD19-negative lymphoma recurrence.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN110799640B_ABST
    Figure CN110799640B_ABST
Patent Text Reader

Abstract

Described herein are methods of producing and utilizing T cells comprising a chimeric antigen receptor (CAR) comprising an extracellular domain that binds to CD79b or to CD79b and CD19. Further, the present invention relates to methods of treating cancer, plasma cell diseases or disorders, or autoimmune diseases or disorders.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The technology described herein relates to immunotherapy. Background Art

[0002] Chimeric antigen receptor (CAR) provides a method for directing cytotoxic T cell responses to target cells expressing selected target antigens (most commonly tumor antigens or tumor-associated antigens). CAR is an adaptation of the T cell receptor, in which the antigen binding domain is replaced by the antigen binding domain of an antibody that specifically binds to the target antigen. The CAR expressed on T cells ("CAR T cells") engages with the target antigen on the surface of the target cell to promote the killing of the target cell.

[0003] Mantle cell lymphoma (MCL) is characterized by an aggressive clinical course, and many patients are highly resistant to currently available therapies. Despite recent advances in treatment, MCL remains an incurable disease. Adoptive immunotherapy using T cells genetically modified to express chimeric antigen receptors (CARs) has shown promise in treating CD19 + The CD19 CAR has great potential for the treatment of B-cell malignancies. However, treatment failure due to antigen-escape has been described in patients receiving CD19 CAR therapy.

[0004] New approaches to treat B-cell malignancies, including MCL, would be beneficial. Summary of the invention

[0005] CAR T cells are cutting-edge therapies that show great promise in treating cancer. The technology has been shown to be particularly effective for various non-solid cancers (e.g., leukemias, lymphomas, and myeloma). One problem encountered in the design of CAR T therapy is that tumors escape through the loss of target antigens or tumor-related factors recognized by CAR. When a tumor downregulates or otherwise loses cell surface expression of a target antigen or factor, it will no longer be effectively attacked by CAR T cells designed to target the antigen or factor. For example, this has been observed in CAR T therapies targeting B cell maturation antigen (BCMA), which is expressed in, for example, B cell malignancies, leukemias, lymphomas, and multiple myeloma. This has also been observed in CAR T therapies targeting CD19.

[0006] The present invention provides chimeric antigen receptor (CAR) polypeptides, each of which includes an extracellular domain, which includes a sequence specifically bound to CD79b, for example, an antigen binding region of an antibody for CD79b. In certain embodiments, the antigen binding region is a single-chain antibody (scFv) for CD79b, which optionally includes a light chain and a heavy chain. The light chain can be at the N-terminus of the heavy chain, or the heavy chain can be at the N-terminus of the light chain.

[0007] The CAR polypeptide may further include one, more or all of a hinge domain, a transmembrane domain, a co-stimulatory domain, and a signaling domain. In various embodiments, the hinge and transmembrane domain are CD8 hinge domains and transmembrane domains; the co-stimulatory domain is a 4-1BB co-stimulatory domain; and / or the signaling domain is a CD3 ζ signaling domain. Therefore, in one embodiment, the CAR of the present invention includes an anti-CD79b scFv, a CD8 hinge and transmembrane domain, a 4-1BB co-stimulatory domain, and a CD3 ζ signaling domain.

[0008] In multiple embodiments, the extracellular domain of the CAR polypeptide further includes a sequence that specifically binds to CD19, for example, an antigen binding region of an antibody to CD19. In certain embodiments, the sequence bound to CD19 includes a single-chain antibody (scFv) to CD19. The scFv may optionally include a light chain and a heavy chain. The light chain may be at the N-terminus of the heavy chain, or the heavy chain may be at the N-terminus of the light chain. In multiple further embodiments, the sequence bound to CD79b is at the N-terminus of the sequence bound to CD19, and in other embodiments, the sequence bound to CD19 is at the N-terminus of the sequence bound to CD79b.

[0009] In various embodiments, the CAR polypeptide comprises a sequence of SEQ ID NO: 1, 2, 10 or 11, or a variant thereof, wherein the sequence optionally deletes the CD8 leader sequence of SEQ ID NO: 3.

[0010] In certain embodiments, the CAR polypeptide includes a CD8 leader sequence of SEQ ID NO: 3 or a variant thereof; an anti-CD79b light chain sequence of SEQ ID NO: 4 or a variant thereof; an anti-CD79b heavy chain sequence of SEQ ID NO: 6 or a variant thereof; a linker sequence of SEQ ID NO: 5 or a variant thereof; a CD8 transmembrane and hinge sequence of SEQ ID NO: 7 or a variant thereof; a 4-1BBICD sequence of SEQ ID NO: 8 or a variant thereof; a CD3ζICD sequence of SEQ ID NO: 9 or a variant thereof; and / or an anti-CD19scFv sequence of SEQ ID NO: 13 or a variant thereof. CARs including all combinations of these sequences are included in the present invention.

[0011] The present invention also provides nucleic acid molecules, each of which includes a sequence encoding a CAR polypeptide as described herein, and a vector including such nucleic acid molecules. In addition, the present invention includes cells (e.g., T cells, such as primary T cells (e.g., human T cells, which may be autologous or allogeneic)), the cells including CAR polypeptides as described herein, or nucleic acid molecules or vectors as described herein. The present invention further includes a pharmaceutical composition, which includes CAR polypeptides, nucleic acid molecules, vectors or cells as described herein.

[0012] The present invention also provides a method for treating a subject suffering from cancer or being at risk of cancer (e.g., B cell malignancies) by administering a pharmaceutical composition as described herein to the subject. In multiple embodiments, the cancer is a lymphoma (e.g., non-Hodgkin's lymphoma, such as, for example, mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL); also see below). The present invention further includes the use of a pharmaceutical composition as described herein in treating a subject (e.g., a subject suffering from cancer or being at risk of cancer as described herein).

[0013] The present invention further provides a method for treating a subject with a CD19 negative lymphoma relapsed after receiving CD19CAR therapy by administering a pharmaceutical composition as described herein to the subject. The present invention further includes the use of a pharmaceutical composition as described herein in treating such a subject.

[0014] The present invention further provides a method for preparing CART cells expressing CD79b-specific or CD79b and CD19-specific CAR polypeptides. The method includes introducing nucleic acid molecules or vectors into T cells (e.g., primary T cells, such as human primary T cells, which may be autologous or allogeneic) as described herein.

[0015] As defined herein, each of the CAR components mentioned in the present disclosure and elsewhere herein may optionally have the sequence of the respective component listed in Example 2 or Example 3, or a variant thereof.

[0016] definition

[0017] For convenience, the meanings of some terms and phrases used in the specification, examples, and appended claims are provided below. Unless otherwise specified or implied from the context, the following terms and phrases include the meanings provided below. These definitions are provided to help describe specific embodiments and are not intended to limit the claimed technology, as the scope of the technology is limited only by the claims. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those commonly understood by those of ordinary skill in the art to which the technology belongs. If there is a clear difference between the use of the terminology of the art and the definitions provided herein, the definitions provided in this specification shall prevail.

[0018] Definitions of commonly used terms in immunology and molecular biology can be found in The Merck Manual of Diagnosis and Therapy, 19th edition, Merck Sharp & Dohme Corp., 2011 (ISBN 978-0-911910-19-3); Robert S. Porter et al. (eds.), The Encyclopedia of Molecular Cell Biology and Molecular Medicine, published by Blackwell Science Ltd., 1999-2012 (ISBN 9783527600908); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc.=VCH Publishers Ltd., 1995 (ISBN 1-56081-569-8); Werner Luttmann, Immunology, Elsevier, 2006; Janeway's Immunobiology, Kenneth Murphy, Allan Mowat, Casey Weaver (eds.), Taylor & Francis Limited, 2014 (ISBN 0815345305, 9780815345305); Lewin's Genes XI, Jones & Bartlett Publishers, 2014 (ISBN 1449659055); Michael Richard Green and Joseph Sambrook, Molecular Cloning: A Laboratory Manual, 4th edition, Cold Spring Harbor Laboratory Press, 2014 (ISBN 1449659055); Harbor Laboratory Press, Cold Spring Harbor, NY, USA (2012) (ISBN 1936113414); Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publishing, Inc., New York, USA (2012) (ISBN 044460149X); Laboratory Methods in Enzymology: DNA, Jon Lorsch (ed.), Elsevier, 2013 (ISBN 0124199542); Current Protocols in Molecular Biology (CPMB), Frederick M. Ausubel (ed.), John Wiley and Sons, 2014 (ISBN 047150338X, 9780471503385), Current Protocols in Protein Science (CPPS), John E. Coligan (ed.), John Wiley and Sons, Inc.[John Wiley and Sons], 2005; and Current Protocols in Immunology (CPI) (John E. Coligan et al. (eds.), John Wiley and Sons, Inc., 2003 (ISBN 0471142735, 9780471142737), the contents of each of which are incorporated herein by reference in their entirety.

[0019] The terms "decrease", "reduced / reduction" or "inhibit" are all used herein to indicate a statistically significant reduction. In some embodiments, "reduced / reduction", "decrease" or "inhibit" generally means a reduction of at least 10% (e.g., without a given treatment or drug) compared to a reference level and can include, for example, a reduction of at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99% or more. As used herein, "reduction" or "inhibition" does not encompass complete inhibition or reduction compared to a reference level. "Complete inhibition" is 100% inhibition compared to a reference level. Where applicable, the reduction may be to a level that is within the normal range for individuals without established disorders.

[0020] The terms "increased / increase", "enhance" or "activate" are all used herein to indicate an increase in a statistically significant amount. In some embodiments, the terms "increased / increase", "enhance" or "activate" may mean an increase of at least 10% compared to a reference level, for example, an increase of at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or up to and including 100%, or any increase between 10%-100% compared to a reference level, or an increase of at least about 2 times, or at least about 3 times, or at least about 4 times, or at least about 5 times, or at least about 10 times, or any increase between 2 times and 10 times or more compared to a reference level. In the context of a marker or symptom, an "increase" is a statistically significant increase in such a level.

[0021] As used herein, "subject" means a person or an animal. Typically, an animal is a vertebrate, such as a primate, a rodent, a domestic animal, or a wild animal. Primates include, for example, chimpanzees, crab-eating monkeys, spider monkeys, and macaques (e.g., rhesus monkeys). Rodents include, for example, mice, rats, marmots, ferrets, rabbits, and hamsters. Domestic animals and wild animals include, for example, cattle, horses, pigs, deer, bison, buffalo, felines (e.g., house cats), canines (e.g., dogs), foxes, wolves, birds (e.g., chickens), emus, ostriches, and fish (e.g., trout, catfish, and salmon). In certain embodiments, the subject is a mammal, such as a primate (e.g., a human). The terms "individual," "patient," and "subject" are used interchangeably herein.

[0022] In many embodiments, the subject is a mammal. The mammal can be a human, non-human primate, mouse, rat, dog, cat, horse or cattle, but is not limited to these examples. Mammals other than humans can be advantageously used as subjects representing animal models of diseases (e.g., cancer). The subject can be male or female, and can be an adult, child or infant.

[0023] The subject may be a subject who has previously been diagnosed or identified as suffering from or having a condition (e.g., lymphoma, leukemia, or another type of cancer in addition thereto) that requires treatment, or one or more complications associated with the condition, and optionally, has been treated for the condition or one or more complications associated with the condition. Alternatively, the subject may also be a subject who has not previously been diagnosed as having such a condition or associated complications. For example, the subject may be a subject who exhibits one or more risk factors for the condition or one or more complications associated with the condition, or a subject who does not exhibit a risk factor.

[0024] A "subject in need" of treatment for a particular disorder may be a subject suffering from, diagnosed as suffering from, or at risk of suffering from the disorder.

[0025] A "disease" is a health state in an animal (e.g., a human) in which the animal is unable to maintain homeostasis and in which the animal's health state will continue to deteriorate if the disease is not ameliorated. In contrast, a "disorder" in an animal is a health state in which the animal is able to maintain homeostasis, but in which the animal is less healthy than it would be in the absence of the disorder. A disorder will not necessarily result in a further decline in the animal's health state if left untreated.

[0026] As used herein, the terms "tumor antigen" and "cancer antigen" are used interchangeably and refer to antigens differentially expressed by cancer cells, and thus can be utilized to target cancer cells. Cancer antigens are antigens that can potentially stimulate a significant tumor-specific immune response. Some of these antigens are encoded by normal cells, but are not necessarily expressed by normal cells. These antigens can be characterized as those antigens that are usually silent (i.e., not expressed) in normal cells, those antigens that are only expressed at certain stages of differentiation, and those antigens (such as embryonic and fetal antigens) that are temporarily expressed. Other cancer antigens are encoded by mutant cell genes, such as oncogenes (e.g., activated ras oncogenes), suppressor genes (e.g., mutant p53) and fusion proteins caused by internal deletions or chromosomal translocations. Still other cancer antigens can be encoded by viral genes, such as genes carried on RNA and DNA tumor viruses. Many tumor antigens have been defined from the perspective of various solid tumors: MAGE 1, 2, and 3, defined by immunity; MART-1 / Melan-A, gp100, carcinoembryonic antigen (CEA), HER2, mucins (i.e., MUC-1), prostate-specific antigen (PSA), and prostatic acid phosphatase (PAP). In addition, viral proteins (such as some viral proteins encoded by hepatitis B virus (HBV), Epstein-Barr virus (EBV), and human papillomavirus (HPV)) have been shown to be important in the development of hepatocellular carcinoma, lymphoma, and cervical cancer, respectively.

[0027] As used herein, the term "chimeric" refers to a product of partial fusion of at least two or more different polynucleotide molecules. In one embodiment, the term "chimeric" refers to a gene expression element produced by manipulating known elements or other polynucleotide molecules.

[0028] In some embodiments, "activation" may refer to the state of a T cell that has been sufficiently stimulated to induce detectable cell proliferation. In some embodiments, activation may refer to induced cytokine production. In other embodiments, activation may refer to detectable effector function. At least, as used herein, "activated T cells" are proliferative T cells.

[0029] As used herein, the term "specific binding" ("specific binding" and "specifically bind") refers to a physical interaction between two molecules, compounds, cells and / or particles, wherein the binding of a first entity to a second entity (i.e., a target) has greater specificity and affinity than its binding to a third entity of a non-target. In some embodiments, specific binding may refer to an affinity of a first entity to a second entity (i.e., a target), which exceeds at least 10 times, at least 50 times, at least 100 times, at least 500 times, at least 1000 times or more of the affinity with a third entity (non-target) under the same conditions. A specific reagent for a given target is an agent that exhibits specific binding to the target under the conditions of the assay used. Non-limiting examples include antibodies or ligands that recognize and bind to homologous binding partners (e.g., stimulatory and / or costimulatory molecules present on T cells) proteins.

[0030] As used herein, "stimulatory ligand" refers to a ligand that can specifically bind to a cognate binding partner (referred to herein as "stimulatory molecule" or "co-stimulatory molecule") on a T cell when present on an antigen presenting cell (APC, e.g., macrophage, dendritic cell, B cell, artificial APC, etc.), thereby mediating the primary response of the T cell (including but not limited to proliferation, activation, initiation of an immune response, etc.). Stimulatory ligands are well known in the art and particularly encompass MHC class I molecules loaded with peptides, anti-CD3 antibodies, superagonist anti-CD28 antibodies, and superagonist anti-CD2 antibodies.

[0031] As used herein, the term "stimulatory molecule" refers to a molecule on a T cell that specifically binds to a cognate stimulatory ligand present on an antigen presenting cell.

[0032] As used herein, the term "costimulatory ligand" includes molecules on APCs that specifically bind to cognate costimulatory molecules on T cells, thereby providing a signal in addition to the original signal provided by, for example, the binding of the TCR / CD3 complex to the MHC molecule loaded with the peptide, and mediating T cell responses, including but not limited to proliferation, activation, differentiation, etc. Costimulatory ligands may include but are not limited to 4-1BBL, OX40L, CD7, B7-1 (CD80), B7-2 (CD86), PD-L1, PD-L2, inducible co-stimulatory ligand (ICOS-L), intercellular adhesion molecules (ICAM), CD30L, CD40, CD70, CD83, HLA-G, MICA, MICB, HVEM, lymphotoxin beta receptor, 3 / TR6, ILT3, ILT4, HVEM, agonists or antibodies that bind to Toll-like receptors, and ligands that specifically bind to B7-H3. Co-stimulatory ligands may also include, but are not limited to, antibodies that specifically bind to co-stimulatory molecules present on T cells, such as, but not limited to, CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and ligands that specifically bind to CD83.

[0033] For example, 4-1BBL is a type 2 transmembrane glycoprotein belonging to the TNFR / TNF ligand superfamily. 4-1BBL is a co-stimulatory ligand combined with the receptor 4-1BB (CD137) expressed on T cells. 4-1BBL is expressed on professional APCs, which include dendritic cells, macrophages, and activated B cells. The 4-1BBL sequence is known for many species, such as human 4-1BBL, also referred to as TNFSF9 (NCBI gene ID: 8744) polypeptide (e.g., NCBI reference sequence NP_003802.1) and mRNA (e.g., NCBI reference sequence NM_003811.3). 4-1BBL may refer to human 4-1BBL, including naturally occurring variants, molecules, and alleles thereof. In some embodiments of any aspect, for example, in veterinary applications, 4-1BBL may refer to, for example, 4-1BBL of dogs, cats, cattle, horses, pigs, etc. Homologs and / or orthologs of human 4-1BBL can be readily identified by one skilled in the art, for example, using the NCBI ortholog search function or searching available sequence data for sequences of a given species that are similar to a reference 4-1BBL sequence.

[0034] "Costimulatory molecules" refer to cognate binding partners on T cells that specifically bind to costimulatory ligands, thereby mediating costimulatory responses of T cells, such as but not limited to proliferation. Costimulatory molecules include but are not limited to MHC class I molecules, BTLA, Toll-like receptors, CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3 and CD83.

[0035] In one embodiment, the term "engineered" and its grammatical equivalents as used herein may refer to one or more human-designed changes in nucleic acids (e.g., nucleic acids within the genome of an organism). In another embodiment, engineering may refer to changes, additions and / or deletions of genes. "Engineered cells" may refer to cells with added, deleted and / or altered genes. The terms "cell" or "engineered cells" and their grammatical equivalents as used herein may refer to cells of human or non-human animal origin.

[0036] As used herein, the term "operably linked" refers to a first polynucleotide molecule, such as a promoter, that is linked to a second transcribable polynucleotide molecule (such as a target gene), wherein the polynucleotide molecules are arranged so that the first polynucleotide molecule affects the function of the second polynucleotide molecule. The two polynucleotide molecules may or may not be part of a single continuous polynucleotide molecule and may be adjacent or non-adjacent. For example, if a promoter regulates or mediates the transcription of a target gene in a cell, the promoter is operably linked to the target gene.

[0037] In the various embodiments as described herein, variants (naturally occurring or otherwise), alleles, homologs, conservatively modified variants and / or conservatively substituted variants of any particular polypeptide described are further contemplated. With respect to amino acid sequences, one of ordinary skill will recognize that a single substitution, deletion or addition of a nucleic acid, peptide, polypeptide or protein sequence that changes a single amino acid or a small percentage of amino acids in the coding sequence is a "conservatively modified variant," wherein such changes result in the replacement of an amino acid with a chemically similar amino acid and retain the desired polypeptide activity. Such conservatively modified variants supplement but do not exclude polymorphic variants, interspecies homologs and alleles consistent with the present disclosure. Variants of the sequences provided herein (see, e.g., Example 2 and Example 3) are included in the present invention.

[0038] A given amino acid may be substituted with a residue having similar physiochemical properties, for example, one aliphatic residue for another (such as Ile, Val, Leu or Ala), or one polar residue for another (such as between Lys and Arg; between Glu and Asp; or between Gln and Asn). Other such conservative substitutions, for example, substitutions of entire regions having similar hydrophobic characteristics, are well known. Polypeptides comprising conservative amino acid substitutions may be tested in any of the assays described herein to confirm that the desired activity, for example, ligand-mediated receptor activity and specificity of the native or reference polypeptide is retained.

[0039] Amino acids can be grouped according to the similarity of the properties of their side chains (see ALLehninger, Biochemistry, 2nd ed., pp. 73-75, Worth Publishers, New York (1975)): (1) nonpolar: Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M); (2) uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q); (3) acidic: Asp (D), Glu (E); (4) basic: Lys (K), Arg (R), His (H). Alternatively, naturally occurring residues can be grouped based on common side-chain properties: (1) hydrophobic: norleucine, Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) acidic: Asp, Gln; (4) basic: His, Lys, Arg; (5) residues affecting chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe. Non-conservative substitutions would entail exchanging a member of one of these classes for another. Specific conservative substitutions include, for example: Ala to Gly or to Ser; Arg to Lys; Asn to Gln or to His; Asp to Glu; Cys to Ser; Gln to Asn; Glu to Asp; Gly to Ala or to Pro; His to Asn or to Gln; Ile to Leu or to Val; Leu to Ile or to Val; Lys to Arg, to Gln or to Glu; Met to Leu, to Tyr or to Ile; Phe to Met, to Leu or to Tyr; Ser to Thr; Thr to Ser; Trp to Tyr; Tyr to Trp; and / or Phe to Val, to Ile or to Leu.

[0040] In some embodiments, a polypeptide described herein (or a nucleic acid encoding such a polypeptide) may be a functional fragment of one of the amino acid sequences described herein. As used herein, a "functional fragment" is a fragment or portion of a peptide that retains at least 50% of the activity of a wild-type reference polypeptide according to an assay known in the art or described herein below. A functional fragment may comprise a conservative substitution of a sequence disclosed herein.

[0041] In some embodiments, the polypeptides described herein can be variants of polypeptides or molecules described herein (see, e.g., sequences in Example 2 and Example 3). In some embodiments, the variant is a conservatively modified variant. For example, conservative substitution variants can be obtained by mutation of the native nucleotide sequence. "Variant" as mentioned herein is a polypeptide substantially homologous to a native or reference polypeptide, but has an amino acid sequence different from a native or reference polypeptide due to one or more deletions, insertions or substitutions. The DNA sequence encoding the variant polypeptide includes one or more additions, deletions or substitutions comprising nucleotides compared to the native or reference DNA sequence, but encodes a sequence of a variant protein or a fragment thereof that retains the activity of a non-variant polypeptide. A variety of site-specific mutagenesis methods based on PCR are known in the art and can be applied by ordinary technicians.

[0042] Variant amino acid or DNA sequence and native or reference sequence (referring to, for example, the sequence of Example 2) can be at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or higher ratio identical.Can determine the homology degree (identity percentage) between native sequence and mutant sequence, for example, by using the computer program (for example, BLASTp or BLASTn, default setting) that can obtain freely for this purpose commonly used on the World Wide Web to compare these two sequences.

[0043] The change of the native amino acid sequence can be accomplished by any of many techniques known to those skilled in the art. For example, a mutation can be introduced at a specific locus by synthesizing an oligonucleotide containing a mutant sequence flanked by restriction sites that allow the fragments of the native sequence to be connected. After connection, the resulting reconstructed sequence encodes an analog with the desired amino acid insertion, substitution or deletion. Alternatively, a site-specific mutagenesis program directed by an oligonucleotide can be used to provide a changed nucleotide sequence with a specific codon that changes according to a desired substitution, deletion or insertion. Techniques for making such changes are well established, including, for example, those disclosed by Walder et al. (Gene 42:133, 1986); Bauer et al. (Gene 37:73, 1985); Craik (BioTechniques, January 1985, 12-19); Smith et al. (Genetic Engineering: Principles and Methods, Plenum Press, 1981); and U.S. Pat. Nos. 4,518,584 and 4,737,462, each of which is incorporated herein by reference in its entirety. Any cysteine ​​residue that is not involved in maintaining the correct conformation of the polypeptide may also be substituted, usually with serine, to improve the oxidative stability of the molecule and prevent abnormal cross-linking. Conversely, one or more cysteine ​​bonds may be added to a polypeptide to improve its stability or promote oligomerization.

[0044] As used herein, the term "DNA" is defined as deoxyribonucleic acid. The term "polynucleotide" is used interchangeably with "nucleic acid" in this article, indicating the polymer of nucleoside. Typically, polynucleotides are composed of nucleosides naturally present in DNA or RNA (for example, adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine and deoxycytidine) connected by phosphodiester bonds. However, the term includes molecules containing nucleosides or nucleoside analogs, which contain chemically or biologically modified bases, modified backbones, etc., whether or not present in naturally occurring nucleic acids, and these molecules may be preferred for certain applications. In the case where the application relates to polynucleotides, it should be understood that both DNA and RNA are provided, and single-stranded and double-stranded forms (and the complement of each single-stranded molecule) are provided in each case. "Polynucleotide sequence" as used herein can refer to polynucleotide materials themselves and / or biochemically characterize the sequence information of specific nucleic acids (that is, a series of letters used as base abbreviations). Unless otherwise indicated, polynucleotide sequences given herein are presented in the 5' to 3' direction.

[0045] As used herein, the term "polypeptide" refers to a polymer of amino acids. The terms "protein" and "polypeptide" are used interchangeably herein. Peptides are relatively short polypeptides, typically about 2 to 60 amino acids in length. The polypeptides used herein typically contain amino acids, such as the most common 20 L-amino acids in proteins. However, other amino acids and / or amino acid analogs known in the art can be used. One or more amino acids in a polypeptide can be modified, for example, by adding chemical entities, such as carbohydrate groups, phosphate groups, fatty acid groups, and joints for conjugation, functionalization, etc. A polypeptide having a non-polypeptide portion covalently or non-covalently associated therewith is still considered a "polypeptide". Exemplary modifications include glycosylation and palmitoylation. Polypeptides can be purified from natural sources, produced using recombinant DNA technology, or synthesized by chemical methods (such as conventional solid phase peptide synthesis, etc.). The term "polypeptide sequence" or "amino acid sequence" used herein can refer to the polypeptide material itself and / or the sequence information (i.e., a series of letters or three letter codes used as abbreviations of amino acid names) that characterizes a polypeptide biochemically. Unless otherwise indicated, the polypeptide sequences given herein are presented in the N-terminal to C-terminal direction.

[0046] In some embodiments, the nucleic acid encoding a polypeptide described herein (e.g., CAR polypeptide) is composed of a vector. In some aspects described herein, the nucleic acid sequence encoding a given polypeptide as described herein or any of its modules is operably connected to a vector. As used herein, the term "vector" refers to a nucleic acid construct designed for delivery to a host cell or for transfer between different host cells. As used herein, a vector may be viral or non-viral. The term "vector" includes any genetic element that can replicate and can transfer a gene sequence to a cell when combined with an appropriate control element. A vector may include, but is not limited to, a cloning vector, an expression vector, a plasmid, a phage, a transposon, a cosmid, an artificial chromosome, a virus, a virion, etc.

[0047] As used herein, the term "expression vector" refers to a vector that guides RNA or polypeptides to be expressed from a sequence connected to a transcriptional regulatory sequence on a vector. The expressed sequence is usually, but not necessarily, heterologous to the cell. The expression vector may contain other elements, for example, the expression vector may have two replication systems, thereby allowing it to be maintained in two organisms, for example, expressed in human cells, and cloned and amplified in a prokaryotic host. The term "expression" refers to the cell process involved in producing RNA and protein and secreting protein under appropriate circumstances, including, but not limited to, for example, transcription, transcript processing, translation and protein folding, modification and processing, where applicable. "Expression products" include RNA transcribed from a gene, and polypeptides obtained by translating mRNA transcribed from a gene. The term "gene" means a nucleic acid sequence that is transcribed (DNA) into RNA in vitro or in vivo when operably linked to an appropriate regulatory sequence. The gene may or may not include regions before and after the coding region, for example, 5' non-translated (5'UTR) or "leader" sequence and 3'UTR or "trailing" sequence, and insertion sequences (introns) between single coding fragments (exons).

[0048] As used herein, the term "viral vector" refers to a nucleic acid vector construct that contains at least one virally derived element and has the ability to be packaged into viral vector particles. The viral vector may contain nucleic acids encoding polypeptides described herein (instead of non-essential viral genes). The vector and / or particle can be used for the purpose of transferring nucleic acids into cells in vitro or in vivo. Many forms of viral vectors are known in the art.

[0049] "Recombinant vector" refers to a vector comprising a heterologous nucleic acid sequence or "transgene" that can be expressed in vivo. It should be understood that in some embodiments, the vectors described herein can be combined with other suitable compositions and therapies. In certain embodiments, the vector is an additional type. The use of a suitable additional vector provides a method for maintaining a target nucleotide in a high copy number extrachromosomal DNA of a subject, thereby eliminating the potential impact of chromosomal integration.

[0050] As used herein, the term "treat / treatment / treating" or "improvement" refers to therapeutic treatment, wherein the purpose is to reverse, alleviate, improve, inhibit, slow down or terminate the progression or severity of a condition, disease or disorder associated with a disease or disorder (e.g., acute lymphoblastic leukemia or other cancers). The term "treatment" includes reducing or alleviating at least one adverse effect or symptom of a condition, disease or disorder. If one or more symptoms or clinical markers are reduced, the treatment is usually "effective". Alternatively, if the progression of the disease is slowed or stopped, the treatment is "effective". That is, "treatment" includes not only the improvement of symptoms or markers, but also the cessation or at least the slowing down of symptom progression or deterioration compared to expectations when there is no treatment. Beneficial or desired clinical results include, but are not limited to, the alleviation of one or more symptoms, the alleviation of the extent of the disease, the stabilization state of the disease (i.e., no deterioration), the delay or slowing down of the progression of the disease, the improvement or alleviation of the disease state, the alleviation (whether partial or complete) and / or the mortality rate of the reduction, whether detectable or undetectable. The term "treatment" of a disease also includes providing symptoms or side effects (including palliative care) that alleviate the disease.

[0051] As used herein, the term "pharmaceutical composition" refers to an active agent in combination with a pharmaceutically acceptable carrier (e.g., a carrier commonly used in the pharmaceutical industry). The phrase "pharmaceutically acceptable" as used herein refers to compounds, materials, compositions, and / or dosage forms that are suitable for contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, with a commensurate reasonable benefit / risk ratio, within the scope of reasonable medical judgment. In some embodiments of any aspect, a pharmaceutically acceptable carrier may be a carrier other than water. In some embodiments of any aspect, a pharmaceutically acceptable carrier may be a cream, an emulsion, a gel, a liposome, a nanoparticle, and / or an ointment. In some embodiments of any aspect, a pharmaceutically acceptable carrier may be an artificial or engineered carrier, for example, a carrier in which a naturally occurring active ingredient is not found.

[0052] As used herein, the term "administering" refers to placing a therapeutic agent or pharmaceutical composition as disclosed herein in a subject by a method or route that results in at least partial delivery of the formulation at the intended site. Pharmaceutical compositions comprising formulations disclosed herein can be administered by any appropriate route that results in effective treatment of the subject.

[0053] The term "statistically significant" or "significant" refers to statistical significance, and generally means a difference of two standard deviations (2SD) or greater.

[0054] Except in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein are to be understood as modified in all instances by the term “about.” When used in conjunction with a percentage, the term “about” may mean ±1%.

[0055] As used herein, the term "comprising" means that there may be other elements in addition to the defined elements given. The use of "comprising" indicates inclusion rather than limitation.

[0056] The term "consisting of" refers to the compositions, methods, and respective components thereof as described herein, excluding any elements not described in the description of that embodiment.

[0057] As used herein, the term "consisting essentially of" refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect one or more basic and novel or functional characteristics of embodiments of the technology.

[0058] Unless the context clearly indicates otherwise, the singular terms "a / an" and "the" include plural referents. Similarly, the word "or" is intended to include "and" (and vice versa) unless the context clearly indicates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. The abbreviation "eg" is derived from the Latin "exempli gratia" and is used herein to represent non-limiting examples. Therefore, the abbreviation "eg" is synonymous with the term "for example".

[0059] In some embodiments of any aspect, the disclosure described herein does not relate to processes for cloning humans, processes for modifying the germline genetic identity of humans, the use of human embryos for industrial or commercial purposes, or processes for modifying the genetic identity of animals that may result in them not providing any substantial medical benefit to humans or animals, and to the animals resulting from these processes.

[0060] Additional terms are defined in the following description of various aspects and embodiments of the technology. BRIEF DESCRIPTION OF THE DRAWINGS

[0061] Figure 1 Surface expression of CD79b, CD79a, CD19, CD37, BCMA, TACI, Fas, CD38, and CD138 on the MCL cell line Jeko-1 is depicted.

[0062] Figure 2 Constructs encoding (i) CD79b and (ii) CD79b and CD19 constructs are depicted.

[0063] Figure 3 is a graph showing the transduction efficiency of the indicated CAR molecules in primary T cells (n=3).

[0064] Figure 4 Are growth curves of untransduced (UTD) cells and cells transduced with the indicated CARs.

[0065] Figure 5 is a graph showing the activation level of CAR-transduced cells.

[0066] Figure 6 is a graph showing the in vitro cytotoxic efficacy of CAR-transduced T cells against Jeko-1 cells (n=2). CD19 (H / L) CAR - black circles; CD79b (L / H) CAR - pentagons; CD79b (H / L) - triangles; UTC - open circles.

[0067] Figure 7 is a graph showing the levels of effector cytokines produced by CAR-transduced cells.

[0068] Fig. 8A Figure 2. Timeline of xenograft model mice receiving Jeko-1 cells followed by CAR T cells.

[0069] Figure 8B is a graph showing the cytotoxic efficacy of CAR T cells against Jeko-1 cells measured by FLUX.

[0070] Figure 8C is a graph showing the number of CAR T cells present in the blood 14 days after injection.

[0071] Fig. 9A Figure 2. Timeline of xenograft model mice receiving MCL PDX cells followed by CAR T cells.

[0072] Fig. 9B is a graph showing the cytotoxic efficacy of CAR T cells against PDX tumors measured by FLUX.

[0073] Fig.10 is a graph showing the activation percentage of bispecific CARs activated by cells expressing CD19 and CD79b (n=3). DETAILED DESCRIPTION

[0074] Described herein are CAR molecules directed against CD79b, which, as described herein, can be used to prevent and treat cancer (e.g., lymphoma (e.g., mantle cell lymphoma (MCL)) and other non-Hodgkin lymphomas (NHL), such as diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL)).

[0075] Also described are bispecific CARs for CD79b and CD19. The bispecific CARs described herein can be advantageously used to reduce the possibility of tumor escape due to the absence of target antigens. In particular, if one or another antigen or factor is downregulated by target cells, the CAR combined with two different tumor-related antigens or factors (e.g., CD79b and CD19) will not lose effectiveness. Similarly, CD79b CAR can be advantageously used to treat subjects who have previously been treated with CD19 CAR but have CD19 negative recurrences.

[0076] Embodiments of the technology described herein relate to finding that CD79b is expressed on cancer cells (including lymphoma cells). Therefore, CARs for CD79b (and optionally CD19) are effective therapies for treating cancer (e.g., lymphoma (e.g., MCL) and other NHLs (such as DLBCL, PMBCL, CLL and SLL)).

[0077] Therefore, one aspect of the present invention described herein relates to a CAR polypeptide, which comprises (a) an extracellular domain, which comprises (i) a sequence specifically binding to CD79b or (ii) a sequence specifically binding to CD79b and a sequence specifically binding to CD19 (e.g., a single-chain antibody sequence; scFv), (b) a hinge and a transmembrane domain, and (c) an intracellular signaling domain. Optionally, the CAR polypeptide also includes a costimulatory domain (as described herein).

[0078] Considerations to consider when preparing and using these and other aspects of the technology are described below.

[0079] Chimeric Antigen Receptor

[0080] The technology described herein provides improved CARs for immunotherapy. CARs and various improvements are discussed below.

[0081] The term "chimeric antigen receptor" or one or more "CARs" used herein refers to an engineered T cell receptor that specifically transplants a ligand or antigen onto a T cell (e.g., a naive T cell, a central memory T cell, an effector memory T cell, or a combination thereof). CARs are also referred to as artificial T cell receptors, chimeric T cell receptors, or chimeric immune receptors.

[0082] CAR places a chimeric extracellular target binding domain that specifically binds to a target (e.g., a polypeptide) expressed on the surface of a cell to be targeted, so that T cells respond to a construct comprising a transmembrane domain of a T cell receptor molecule and one or more intracellular domains (including a signaling domain). In one embodiment, the chimeric extracellular target binding domain comprises one or more antigen binding domains of an antibody, which specifically binds to an antigen expressed on a cell to be targeted to produce a T cell response. In another embodiment, the chimeric extracellular target binding domain comprises one or more antigen binding domains of a first antibody (the first antibody specifically binds to a first antigen expressed on a cell targeted by a T cell response), and further comprises one or more antigen binding domains of a second antibody (the second antibody specifically binds to a second antigen expressed on a cell targeted by a T cell response). The properties of one or more intracellular signaling domains of CAR may vary as known in the art and disclosed herein, but when the target / antigen binding domain binds to a target / antigen on the surface of a target cell, the chimeric target / antigen binding domain makes the receptor sensitive to signaling activation.

[0083] Regarding the intracellular signaling domain, the so-called "first generation" CAR includes those CARs that only provide CD3ζ (CD3zeta) signals when the antigen is bound. The so-called "second generation" CAR includes those CARs that provide costimulation (e.g., CD28 or CD137) and activation (CD3ζ) domains, and the so-called "third generation" CAR includes those CARs that provide multiple costimulation (e.g., CD28 and CD137) domains and activation domains (e.g., CD3ζ). In multiple embodiments, CAR is selected to have high affinity or avidity for the target / antigen. For example, compared with naturally occurring T cell receptors, antibody-derived targets or antigen binding domains generally have higher affinity and / or avidity for the target antigen. This feature, combined with the high specificity of antibodies that can be selected, provides a highly specific T cell targeting of CAR T cells.

[0084] As used herein, "CAR T cells" or "CAR-T" refers to T cells expressing CAR. When expressed in T cells, CAR has the ability to redirect T cell specificity and reactivity to selected targets in a non-MHC restricted manner using the antigen binding properties of monoclonal antibodies. Non-MHC restricted antigen recognition enables CAR-expressing T cells to recognize antigens independent of antigen processing, thereby bypassing the main mechanism of tumor escape.

[0085] As used herein, the term "extracellular target binding domain" refers to a polypeptide found outside the cell that is sufficient to promote binding to the target. The extracellular target binding domain will specifically bind to its binding partner. Typically, the extracellular target binding domain may include an antigen binding domain of an antibody or ligand that recognizes and binds to a cognate binding partner protein. In this article, a ligand is a molecule that specifically binds to a portion of a protein and / or receptor. The cognate binding partner of the ligand that can be used in the methods and compositions described herein can typically be found on the surface of a cell. Ligand: cognate partner binding can result in changes in the receptor carrying the ligand, or activate a physiological response, for example, activating a signaling pathway or cascade reaction. In one embodiment, the ligand may be non-genomic native. Optionally, the ligand has a conserved function on at least two species.

[0086] Antibody Reagents

[0087] In various embodiments, the CAR described herein comprises an antibody agent or an antigen binding domain thereof as an extracellular target binding domain.

[0088] As used herein, the term "antibody reagent" refers to a polypeptide comprising at least one immunoglobulin variable domain or immunoglobulin variable domain sequence and specifically binding to a given antigen. The antibody reagent may comprise an antibody or a polypeptide containing the antigen binding domain of an antibody. In some embodiments of any aspect, the antibody reagent may comprise a monoclonal antibody or a polypeptide containing the antigen binding domain of a monoclonal antibody. For example, an antibody may include a heavy (H) chain variable region (abbreviated herein as VH) and a light (L) chain variable region (abbreviated herein as VL). In another example, the antibody includes two heavy (H) chain variable regions and two light (L) chain variable regions. The term "antibody reagent" encompasses antigen-binding fragments of antibodies (e.g., single-chain antibodies, Fab and sFab fragments, F(ab')2, Fd fragments, Fv fragments, scFv, CDR and domain antibody (dAb) fragments (see, e.g., deWildt et al., Eur J. Immunol. [European Journal of Immunology] 26(3):629-639, 1996; which is incorporated herein by reference in its entirety), as well as intact antibodies. Antibodies can have the structural characteristics of IgA, IgG, IgE, IgD or IgM (as well as subtypes and combinations thereof). Antibodies can be from any source, including mouse, rabbit, pig, rat and primates (human and non-human primates) and primatized antibodies. Antibodies also include intermediate antibodies, humanized antibodies, chimeric antibodies, etc. Fully human antibody binding domains can be selected from, for example, phage display libraries using methods known to those of ordinary skill in the art.

[0089] The VH and VL regions can be further subdivided into hypervariable regions, called "complementarity determining regions" ("CDRs"), interspersed with more conserved regions called "framework regions" ("FRs"). The extent of the framework regions and CDRs has been precisely defined (see, Kabat, EA et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242, and Chothia et al., J. Mol. Biol [Journal of Molecular Biology] 196:901-917, 1987; which are incorporated herein by reference in their entirety). Each VH and VL is typically composed of three CDRs and four FRs arranged from amino-terminus to carboxyl-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.

[0090] In one embodiment, the antibody or antibody reagent is not a human antibody or antibody reagent (i.e., the antibody or antibody reagent is a mouse), but has been humanized. "Humanized antibody or antibody reagent" refers to a non-human antibody or antibody reagent that has been modified at the protein sequence level to increase its similarity to a naturally occurring antibody or antibody reagent variant of a human being. One method of humanizing antibodies employs transplanting mouse or other non-human CDRs onto a human antibody framework.

[0091] In one embodiment, the extracellular target binding domain of CAR comprises or is substantially composed of a single-chain Fv (scFv) fragment, which is produced by fusing the VH and VL domains of an antibody (usually a monoclonal antibody) with a flexible linker peptide. In various embodiments, the scFv is fused with a transmembrane domain and a T cell receptor intracellular signaling domain, for example, an engineered intracellular signaling domain as described herein.

[0092] Antibody binding domains and means of selecting and cloning them are well known to those of ordinary skill in the art.

[0093] In one embodiment, the extracellular domain of the CAR polypeptide comprises an antibody reagent or its antigen binding domain as an extracellular target binding domain, and the extracellular target binding domain is directed to CD79b. In another embodiment, the extracellular domain of the CAR polypeptide comprises (i) an antibody reagent or its antigen binding domain as an extracellular target binding domain, and the extracellular target binding domain is directed to CD79b, and (ii) an antibody reagent or its antigen binding domain as an extracellular target binding domain, and the extracellular target binding domain is directed to CD19.

[0094] Thus, for example, in one embodiment, the extracellular domain of the CAR polypeptide comprises, consists essentially of, or consists of: SEQ ID NO:4 light chain sequence and / or SEQ ID NO:6 heavy chain sequence, or comprises, consists essentially of, or consists of: SEQ ID NO:4 and / or SEQ ID NO:6 has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity One or more sequences. The light chain and heavy chain sequences can be in any order, for example, the light chain sequence can be at the N-terminus of the heavy chain sequence, or the heavy chain sequence can be at the N-terminus of the light chain sequence. In various embodiments, the light chain and heavy chain sequences are separated from each other by a linker sequence (e.g., a glycine-rich sequence; e.g., SEQ ID NO:5).

[0095] In another example, the extracellular domain of the CAR polypeptide comprises the following, is substantially composed of the following, or is composed of the following: (i) comprising a sequence (SEQ ID NO: 12) for scFv for CD79b, the sequence including a light chain (SEQ ID NO: 4), a joint (SEQ ID NO: 5) and a heavy chain (SEQ ID NO: 6), (ii) an optional joint (SEQ ID NO: 5), and (iii) comprising a sequence (SEQ ID NO: 13) for scFv for CD19. The extracellular domain of the CAR polypeptide may optionally have one or more sequences having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity with one or more of these sequences. In addition, the order of the light chain and the heavy chain (for example, in CD79b scFv) may be in opposite positions.

[0096] In one embodiment, the CAR polypeptide comprises one or more mutations in its coding region to produce a variant sequence as described herein. Those skilled in the art will be able to introduce mutations into the nucleotide sequence of a gene or gene product using standard techniques. For example, point mutations can be introduced by site-directed mutagenesis (PCR technology). Site-directed mutagenesis kits are commercially available, for example, by New England Biolabs; Ipswich, Massachusetts. Non-limiting examples of alternative methods for introducing point mutations into the nucleotide sequence of a gene or gene product include cassette mutagenesis or whole plasmid mutagenesis.

[0097] In one embodiment, the CAR useful in the technology described herein comprises at least two antigen-specific targeting regions (e.g., SEQ ID NO: 12 and / or 13) in the extracellular domain, the transmembrane domain, and the intracellular signaling domain. In such embodiments, the two or more antigen-specific targeting regions of this bispecific CAR target at least two different antigens and can be arranged in tandem and separated by a linker sequence (e.g., SEQ ID NO: 5).

[0098] Target / Antigen

[0099] Generally, CAR can target any cell surface part. Most commonly, the target will be a cell surface polypeptide that is differentially or preferentially expressed on cells that wish to target to produce T cell responses. In this regard, tumor antigens or tumor-associated antigens provide attractive targets, providing targeted tumor cells while avoiding or at least limiting the means of collateral damage to non-tumor cells or tissues. CARs for CD79b, or both CD79b and CD19 are described herein. Non-limiting examples of other tumor antigens or tumor-associated antigens include CEA, immature laminin receptor, TAG-72, HPV E6 and E7, BING-4, calcium-activated chloride channel 2, cyclin B1, 9D7, Ep-CAM, EphA3, Her2 / neu, telomerase, mesothelin, SAP-1, survivin, BAGE family, CAGE family, GAGE ​​family, MAGE family, SAGE family, XAGE family, NY-ESO-1 / LAGE-1, PRAME, SSX-2, Melan-A / MART-1, Gp100 / pmel17, tyrosinase, TRP-1 / -2, MC1R, BRCA1 / 2, CDK4, MART-2, p53, Ras, MUC1 and TGF-βRII. CAR for one or more of these antigens can be used in combination with CAR for CD79b, or CD79b and CD19, as described herein, as determined by those skilled in the art.

[0100] Hinge and TM domains

[0101] Each of the CARs described herein can include a hinge domain that separates the extracellular target binding domain from the T cell membrane.

[0102] As used herein, "hinge domain" refers to an amino acid region that allows the binding moiety and T cell membrane to separate and generate flexibility. The length of the flexible hinge also allows better binding to relatively inaccessible epitopes, for example, longer hinge regions allow optimal binding. Those skilled in the art will be able to determine the appropriate hinge for a given CAR target. In one embodiment, the transmembrane domain of any CAR polypeptide described herein or a fragment thereof comprises a CD8 or 4-1BB hinge domain.

[0103] Each CAR as described herein includes a transmembrane domain connecting an extracellular target binding domain to an intracellular signaling domain.

[0104] As used herein, "transmembrane domain" (TM domain) refers to the generally hydrophobic region of CAR, which passes through the plasma membrane of the cell. The TM domain can be a transmembrane region of a transmembrane protein (eg, type I transmembrane protein or other transmembrane protein) or a fragment thereof, an artificial hydrophobic sequence, or a combination thereof. Although specific examples are provided herein and used in examples, other transmembrane domains will be apparent to those skilled in the art and can be used in conjunction with alternative embodiments of the technology. The selected transmembrane region or its fragment preferably does not interfere with the intended function of CAR. As used with respect to the transmembrane domain of a protein or polypeptide, "its fragment" refers to a portion of a transmembrane domain sufficient to anchor or attach a protein to the surface of a cell.

[0105] In one embodiment, the transmembrane domain of any CAR polypeptide described herein or its fragment includes a transmembrane domain selected from the transmembrane domain of CD8 or 4-1BB. In an alternative embodiment of any aspect, the transmembrane domain of CAR described herein or its fragment includes a transmembrane domain of a transmembrane domain of an α, β or ζ chain selected from the following items: T cell receptor, CD28, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, LFA-1 (CD1 la, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRFl), CD1 60. CD19, IL2Rβ, IL2Rγ, IL7Ra, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CDl ld, ITGAE, CD103, ITGAL, CDl la, LFA-1, ITGAM, CDl lb, ITGAX, CDl lc, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1(CD226), SLAMF4(CD244, 2B4), CD84, CD96(Tactile), CEACAM1, CRTAM, Ly9(CD229), CD160(BY55), PSGL 1. CD100 (SEMA4D), SLAMF6 (NTB-A, Lyl08), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​PAG / Cbp, NKp44, NKp30, NKp46, NKG2D, and / or NKG2C.

[0106] CD8 is an antigen preferentially found on the cell surface of cytotoxic T lymphocytes. CD8 mediates cell-cell interactions within the immune system and acts as a T cell co-receptor. CD8 consists of α (CD8a) and β (CD8b) chains. CD8a sequences of many species are known, for example, human CD8a (NCBI gene ID: 925) polypeptide (NCBI reference sequence NP_001139345.1) and mRNA (e.g., NCBI reference sequence NM_000002.12). CD8 may refer to human CD8, including naturally occurring variants, molecules and alleles thereof. In some embodiments of any aspect, for example, in veterinary applications, CD8 may refer to, for example, CD8 of dogs, cats, cattle, horses, pigs, etc. Those skilled in the art can easily identify homologs and / or orthologs of human CD8, for example, using the NCBI ortholog search function or searching for available sequence data of sequences similar to the reference CD8 sequence of a given species.

[0107] In one embodiment, the CD8 hinge and transmembrane sequence comprises the sequence of SEQ ID NO:7; or comprises a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the sequence of SEQ ID NO:7.

[0108] Costimulatory domain

[0109] CAR described herein can each optionally include one or more intracellular domains or costimulatory domains of costimulatory molecules.As used herein, the term "costimulatory domain" refers to the intracellular signaling domain of a costimulatory molecule.Costimulatory molecules are cell surface molecules other than antigen receptors or Fc receptors, which provide a second signal required for the function of effective activation and T lymphocytes after binding to an antigen.Illustrative examples of such costimulatory molecules include CARD11, CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD134 (OX40), CD137 (4-1BB), CD150 (SLAMF1), CD152 (CTLA4), CD223 (LAG3), CD270 (HVEM), CD273 (PD-L2), CD274 (PD-L1), CD278 (ICOS), DAP10, LAT, NKD2C SLP76, TRIM and ZAP70. In one embodiment, the intracellular domain is the intracellular domain of 4-1BB.

[0110] Therefore, in one embodiment, the CAR polypeptide further comprises an intracellular domain. As used herein, "intracellular domain" refers to a sequence completely contained within a cell. In one embodiment, the intracellular domain refers to the intracellular domain of a receptor. The intracellular domain can interact with the interior of a cell. Regarding the intracellular domain of a receptor, the intracellular domain can play a role in conveying signal transduction. The intracellular domain of a receptor can include enzymatic activity.

[0111] In one embodiment, the intracellular domain is the intracellular domain (ICD) of 4-1BB. In one embodiment, the 4-1BB intracellular domain comprises the sequence of SEQ ID NO: 8; or comprises a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity with the sequence of SEQ ID NO: 8.

[0112] Intracellular signaling domain

[0113] CAR as described herein comprises an intracellular signaling domain. "Intracellular signaling domain" refers to a part of the CAR polypeptide that is involved in transducing information of an effective CAR bound to a target antigen to the interior of an immune effector cell to induce effector cell functions, such as activation, cytokine production, proliferation, and cytotoxic activity, including the release of cytotoxic factors to target cells bound to CAR, or other cellular responses triggered by antigen binding to an extracellular CAR domain.

[0114] CD3 is a T cell co-receptor that promotes T lymphocyte activation when it simultaneously engages in appropriate co-stimulation (e.g., binding of co-stimulatory molecules). The CD3 complex consists of 4 different chains; mammalian CD3 consists of one CD3γ chain, one CD3δ chain, and two CD3ε chains. These chains bind to molecules called T cell receptors (TCRs) and CD3ζ to generate activation signals in T lymphocytes. The complete TCR complex contains the TCR, CD3ζ, and the complete CD3 complex.

[0115] In some embodiments of any aspect, the CAR polypeptide described herein comprises an intracellular signaling domain comprising an activation motif based on immunoreceptor tyrosine or an ITAM from CD3ζ (CD3 zeta). In some embodiments of any aspect, the ITAM includes three motifs of the ITAM of CD3ζ (ITAM3). In some embodiments of any aspect, three motifs of the ITAM of CD3ζ are mutated.

[0116] ITAMs are referred to as primary signaling domains that regulate the primary activation of the TCR complex in a stimulatory or inhibitory manner. Primary signaling domains that act in a stimulatory manner may contain signaling motifs, which are referred to as immunoreceptor tyrosine-based activation motifs or ITAMs. Non-limiting examples of ITAMs containing intracellular signaling domains particularly used in this technology include those derived from TCRζ, FcRγ, FcRβ, CD3γ, CD3θ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d.

[0117] Those skilled in the art will be able to introduce mutations into the nucleotide sequence of a gene or gene product (e.g., ITAM) using standard techniques. For example, point mutations can be introduced by site-directed mutagenesis (PCR technology). Site-directed mutagenesis kits are commercially available, for example, through New England Biolabs; Ipswich, Massachusetts. Non-limiting examples of alternative methods for introducing point mutations into the nucleotide sequence of a gene or gene product include cassette mutagenesis or full plasmid mutagenesis.

[0118] In one embodiment, the ITAM used in the CAR is an alternative based on CD3ζ, including an ITAM mutated from CD3ζ (which contains 3 ITAM motifs), a truncation of CD3ζ, and an alternative splice variant called CD3ε, CD3θ, and an artificial construct engineered to express a fusion protein between CD3ε or CD3θ and CD3ζ

[0119] In one embodiment, the CD3ζ intracellular signaling sequence corresponds to the amino acid sequence of SEQ ID NO:9; or comprises the sequence of SEQ ID NO:9; or comprises a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the sequence of SEQ ID NO:9.

[0120] A more detailed description of CAR and CAR T cells can be found in: Maus et al., Blood 123:2624-2635, 2014; Reardon et al., Neuro-Oncology 16:1441-1458, 2014; Hoyos et al., Haematologica 97:1622, 2012; Byrd et al., J. Clin. Oncol. 32:3039-3047, 2014; Maher et al., Cancer Res. 69:4559-4562, 2009; and Tamada et al., Clin. Cancer Res. 18:6436-6445, 2012; each of which is incorporated herein by reference in its entirety.

[0121] In one embodiment, the CAR polypeptide further comprises a CD8 leader sequence. As used herein, a "leader sequence", also referred to as a leader RNA, refers to a region of an mRNA directly upstream of the start codon. The leader sequence may be important for the regulation of transcript translation.

[0122] In one embodiment, the CD8 leader sequence corresponds to the amino acid sequence of SEQ ID NO:3; or comprises SEQ ID NO:3; or comprises a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to SEQ ID NO:3.

[0123] In one embodiment, the CAR also includes a joint domain. As used herein, "joint domain" refers to an oligopeptide or polypeptide region of about 2 to 100 amino acids in length, which connects any domain / region of CAR as described herein together. In some embodiments, the joint may include or consist of flexible residues such as glycine and serine, so that adjacent protein domains can move freely relative to each other. When it is desired to ensure that two adjacent domains do not interfere with each other spatially, a longer joint can be used. The joint may be cleavable or non-cleavable. Examples of cleavable joints include 2A joints (e.g., T2A), 2A-like joints or their functional equivalents and combinations thereof. In one embodiment, the joint region is T2A derived from Thosea asigna virus. Non-limiting examples of joints include joints derived from vein flat moth beta tetrasomic virus and joints derived from internal ribosome entry site (IRES) sequences.

[0124] In one embodiment, the CAR as described herein further comprises a reporter molecule, for example, to allow non-invasive imaging (e.g., positron emission tomography PET scanning). In a bispecific CAR comprising a reporter molecule, the first extracellular binding domain and the second extracellular binding domain may include different or identical reporter molecules. In bispecific CAR T cells, the first CAR and the second CAR may express different or identical reporter molecules. In another embodiment, the CAR described herein further comprises a reporter molecule (e.g., hygromycin phosphotransferase (hph)), which can be imaged alone or with a substrate or chemical (e.g., 9-[4-[ 18 F]fluoro-3-(hydroxymethyl)butyl]guanine ([ 18 In another embodiment, the CAR described herein further comprises a method for detecting the presence of a CAR using a non-invasive technique (e.g., 64 Cu 2+ Functionalized gold nanoparticles (GNPs) are nanoparticles that are easily imaged. CAR T cell labeling for non-invasive imaging is reviewed, for example, Bhatnagar et al., Integr. Biol. (Camb) [Integrated Biology (Cambodia)] 5(1): 231-238, 2013, and Keu et al., Sci. Transl. Med. [Science Translational Medicine] 9(373), 2017, which are incorporated herein by reference in their entirety.

[0125] GFP and mCherry are shown herein to be fluorescent labels that can be used for imaging CAR expressed on T cells (e.g., CAR T cells). It is expected that substantially any fluorescent protein known in the art can be used as a fluorescent label for this purpose. For clinical applications, the CAR does not need to include a fluorescent label or a fluorescent protein.

[0126] Another aspect of the present invention relates to a CAR polypeptide comprising a sequence selected from SEQ ID NO: 1, 2, 10 and 11 (optionally, wherein the CD8 leader sequence of SEQ ID NO: 3 is omitted) having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity. Another aspect of the present invention relates to a CAR polypeptide comprising a sequence selected from SEQ ID NO: 1, 2, 10 and 11 (optionally, wherein the CD8 leader sequence of SEQ ID NO: 3 is omitted).

[0127] Another aspect of the invention described herein relates to a polypeptide complex comprising two or more (e.g., two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more) of any CAR polypeptides described herein. In one embodiment, the polypeptide complex comprises three of any CAR polypeptides described herein.

[0128] Another aspect of the present invention relates to a mammalian cell comprising any CAR polypeptide described herein; or a nucleic acid encoding any CAR polypeptide described herein. In one embodiment, the mammalian cell comprises an antibody, an antibody reagent, an antigen binding portion thereof, or any CAR polypeptide described herein, or a nucleic acid encoding such an antibody, an antibody reagent, an antigen binding portion thereof, or any CAR polypeptide described herein. The mammalian cell or tissue may be of human, primate, hamster, rabbit, rodent, cattle, pig, sheep, horse, goat, dog or cat origin, but any other mammalian cell may also be used. In a preferred embodiment of any aspect, the mammalian cell is human.

[0129] In one embodiment, the cell is a T cell. In an alternative embodiment of any aspect, the cell is an immune cell. As used herein, "immune cell" refers to a cell that plays a role in an immune response. Immune cells have a hematopoietic origin and include lymphocytes, such as B cells and T cells; natural killer cells; bone marrow cells, such as monocytes, macrophages, eosinophils, mast cells, basophils, and granulocytes. In some embodiments, the cell is a T cell; NK cells; NKT cells; lymphocytes, such as B cells and T cells; and bone marrow cells, such as monocytes, macrophages, eosinophils, mast cells, basophils, and granulocytes.

[0130] In one embodiment, the cell is obtained from an individual suffering from or diagnosed with cancer, a plasma cell disorder, or an autoimmune disease.

[0131] As used herein, "cancer" may refer to an over-proliferation of cells whose unique properties - loss of normal cellular control - result in unregulated growth, lack of differentiation, local tissue infiltration and metastasis, and may be, for example, a lymphoma, leukemia, multiple myeloma or a solid tumor. In certain instances, the cancer is any type of B-cell malignancy. Non-limiting examples of B-cell malignancies include diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), marginal zone lymphoma, Burkitt's lymphoma, hairy cell leukemia (HCL), Hodgkin's lymphoma, nodular lymphocyte-predominant Hodgkin's lymphoma, mucosa-associated lymphoid tissue lymphoma (MALT), lymphoplasmacytic lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, lymphomatoid granulomatosis, primary central nervous system lymphoma, ALK-positive large B-cell lymphoma, plasmablastic lymphoma, large B-cell lymphoma due to HHV8-associated multicentric Castleman disease, and unclassifiable B-cell lymphoma.

[0132] Non-limiting examples of leukemia include acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL). In one embodiment, the cancer is ALL or CLL. Non-limiting examples of solid tumors include adrenocortical tumors, alveolar soft tissue sarcomas, epithelial cancer, chondrosarcomas, colorectal cancer, desmoid tumors, desmoplastic small round cell tumors, endocrine tumors, endodermal sinus tumors, epithelioid hemangioendothelioma, Ewing's sarcoma, germ cell tumors (solid tumors), giant cell tumors of bone and soft tissue, hepatoblastoma, hepatocellular carcinoma, melanoma, nephroma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), osteosarcoma, paraspinal sarcoma, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, synovial sarcoma and Wilms' tumor. Solid tumors can be found in bones, muscles or organs, and can be sarcomas or epithelial cancers. It is contemplated that any aspect of the invention described herein can be used to treat all types of cancer, including cancers not listed in this application.As used herein, the term "tumor" refers to an abnormal growth of cells or tissue, for example, of a malignant or benign type.

[0133] As used herein, an "autoimmune disease or disorder" is characterized by the inability of a person's immune system to distinguish between foreign cells and healthy cells. This causes a person's immune system to target its healthy cells to cause programmed cell death. Non-limiting examples of autoimmune diseases or disorders include inflammatory arthritis, type 1 diabetes, multiple sclerosis, psoriasis, inflammatory bowel disease, SLE, and vasculitis, allergic inflammation (such as allergic asthma, atopic dermatitis, and contact hypersensitivity), rheumatoid arthritis, multiple sclerosis (MS), systemic lupus erythematosus, Graves' disease (hyperthyroidism), Hashimoto's thyroiditis (hypothyroidism), chronic graft-versus-host disease, hemophilia (with antibodies to clotting factors), celiac disease, Crohn's disease and ulcerative colitis, Guillain-Barré syndrome, primary biliary cirrhosis / cirrhosis, sclerosing cholangitis, autoimmune Hepatitis, Raynaud's phenomenon, scleroderma, Sjögren's syndrome, Goodpasture's syndrome, Wegener's granulomatosis, polymyalgia rheumatica, temporal arteritis / giant cell arteritis, chronic fatigue syndrome (CFS), psoriasis, autoimmune Addison's disease, ankylosing spondylitis, acute diffuse encephalomyelitis, antiphospholipid antibody syndrome, aplastic anemia, idiopathic thrombocytopenic purpura, myasthenia gravis, opsoclonus-myoclonus syndrome, optic neuritis, Ord's thyroiditis, pemphigus, pernicious anemia, canine polyarthritis, Reiter's syndrome, Takayasu's arteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, and fibromyalgia (FM).

[0134] In one embodiment, the mammalian cells are obtained from a patient suffering from an immune system disorder that results in abnormally low immune system activity, or an immunodeficiency disorder that impairs a person's ability to fight off foreign cells (eg, viral or bacterial cells).

[0135] Plasma cells are white blood cells produced by B lymphocytes, and their function is to generate and release antibodies required for anti-infection. As used herein, "plasma cell disorders or diseases" are characterized by abnormal proliferation of plasma cells. Abnormal plasma cells can "crowd out" healthy plasma cells, which leads to reduced ability to resist foreign objects (such as viruses or bacterial cells). Non-limiting examples of plasma cell disorders include amyloidosis, Waldenstrom's macroglobulinemia, osteosclerotic myeloma (POEMS syndrome), monoclonal gammopathy of unknown significance (MGUS) and plasma cell myeloma.

[0136] T cells can be obtained from a subject using standard techniques known in the art, for example, by isolating T cells from peripheral blood taken from a patient.

[0137] Cells (e.g., T cells) can be engineered to contain any CAR polypeptide described herein; or nucleic acids encoding any CAR polypeptide described herein. In one embodiment, the CAR polypeptide described herein is contained in a lentiviral vector. The lentiviral vector is used to express the CAR polypeptide in cells using standard infection techniques.

[0138] Retroviruses (such as lentiviruses) provide a convenient platform for delivering nucleic acid sequences encoding genes or chimeric genes of interest. The selected nucleic acid sequence can be inserted into a vector and packaged in retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to cells, for example, in vitro or ex vivo. Retroviral systems are well known in the art, as described below, for example, U.S. Patent No. 5,219,740; Kurth and Bannert (2010) "Retroviruses: Molecular Biology, Genomics and Pathogenesis" Calster Academic Press (ISBN: 978-1-90455-55-4); and Hu and Pathak Pharmacological Reviews 2000 52: 493-512; which are incorporated herein by reference in their entirety. Lentiviral systems for effective DNA delivery can be purchased from OriGene; Rockville, Maryland. In an alternative embodiment, the CAR polypeptides of any CAR described herein are expressed in mammalian cells by transfection or electroporation of an expression vector comprising a nucleic acid encoding CAR. Transfection or electroporation methods are known in the art.

[0139] The CAR polypeptide efficient expression of any CAR polypeptide described herein can be assessed using standard assays for detecting mRNA, DNA or gene products of nucleic acids encoding the CAR. For example, RT-PCR, FACS, Northern blot, protein blot, ELISA or immunohistochemistry.

[0140] In one embodiment, the CAR polypeptide in any CAR polypeptide described herein is constitutively expressed. In one embodiment, the CAR polypeptide in any CAR polypeptide described herein is encoded by a recombinant nucleic acid sequence.

[0141] One aspect of the invention described herein relates to a method of treating cancer, plasma cell disorders, amyloidosis, or an autoimmune disease in a subject, the method comprising: engineering T cells to comprise any CAR polypeptide described herein on the surface of the T cells; administering the engineered T cells to the subject.

[0142] Another aspect of the invention described herein relates to a method of treating cancer, a plasma cell disorder, or an autoimmune disease in a subject, the method comprising administering to a cell any of the CAR polypeptides described herein or a nucleic acid encoding any of the CAR polypeptides described herein.

[0143] In one embodiment, the method further comprises activating or stimulating the CAR-T cells prior to administering the cells to the subject, e.g., according to the methods described elsewhere herein.

[0144] In one embodiment, the cancer cells comprise the tumor antigen CD79b, or both the tumor antigens CD79b and CD19.

[0145] Application

[0146] In some embodiments, the methods described herein relate to treating a subject with or diagnosed with cancer, plasma cell disease or disorder or autoimmune disease or disorder with a mammalian cell comprising any CAR polypeptide described herein or a nucleic acid encoding any CAR polypeptide described herein. As used herein, "CAR T cells described herein" refers to a mammalian cell comprising any CAR polypeptide described herein or a nucleic acid encoding any CAR polypeptide described herein. As used herein, "disorder" refers to cancer, plasma cell disease or disorder, or autoimmune disease or disorder. Subjects with a disorder can be identified by a doctor using an existing method for diagnosing the disorder. The symptoms and / or complications of the disorder characterize these disorders and contribute to diagnosis, and these symptoms and / or complications are well known in the art, including but not limited to fatigue, persistent infection, and persistent bleeding. For a given disorder, tests that may contribute to diagnosis (such as the disorder) include but are not limited to blood screening and bone marrow testing, and these tests are known in the art. Family history of the disorder or risk factors exposed to the disorder can also help determine whether the subject may have the disorder or help diagnose the disorder.

[0147] The compositions described herein can be administered to subjects suffering from or diagnosed with a disorder. In some embodiments, the methods described herein include administering to a subject an effective amount of activated CAR T cells described herein to alleviate the symptoms of the disorder. As used herein, "alleviating the symptoms of the disorder" is to improve any disorder or symptom associated with the disorder. Compared to an equivalent untreated control, this reduction measured by any standard technique is at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95%, 99% or higher. A variety of methods for administering the compositions described herein to a subject are known to those skilled in the art. In one embodiment, the compositions described herein are administered systemically or topically. In a preferred embodiment, the compositions described herein are administered intravenously. In another embodiment, the compositions described herein are administered to a tumor site.

[0148] As used herein, the term "effective amount" refers to the amount of activated CAR T cells required to alleviate at least one or more symptoms of a disease or disorder, and relates to the amount of a cell preparation or composition sufficient to provide the desired effect. Therefore, the term "therapeutically effective amount" refers to the amount of activated CAR T cells sufficient to provide a specific anti-disease effect when applied to a typical subject. In many cases, the effective amount as used herein will also include an amount sufficient to delay the progression of disease symptoms, change the course of symptomatic disease (for example, but not limited to, slowing the progression of the disease) or reverse the symptoms of the disease. Therefore, it is generally impossible to specify an exact "effective amount". However, for any given situation, an appropriate "effective amount" can be determined by a person of ordinary skill in the art using only routine experiments.

[0149] The effective amount, toxicity and therapeutic efficacy can be evaluated by standard pharmaceutical procedures in cell culture or experimental animals. The dosage may vary depending on the dosage form used and the route of administration used. The dose ratio between toxicity and therapeutic efficacy is the therapeutic index and can be expressed as a ratio LD50 / ED50. Compositions and methods showing a large therapeutic index are preferred. Initially, the therapeutically effective dose can be estimated from a cell culture assay. In addition, the dosage can be formulated in an animal model to reach a circulating plasma concentration range, which includes an IC50 (i.e., the concentration of activated CAR T cells that achieves half-maximal inhibition of symptoms) measured in a cell culture or in an appropriate animal model. The level in plasma can be measured, for example, by high performance liquid chromatography. The effect of any particular dose can be monitored by a suitable bioassay, for example, a determination for bone marrow testing, etc. The dosage can be determined by a doctor and adjusted as needed to adapt to the observed therapeutic effect.

[0150] In one aspect of the present invention, the technology described herein relates to a pharmaceutical composition comprising activated CAR T cells as described herein and optionally a pharmaceutically acceptable carrier. The active ingredient of the pharmaceutical composition comprises at least activated CAR T cells as described herein. In some embodiments, the active ingredient of the pharmaceutical composition consists essentially of activated CAR T cells as described herein. In some embodiments, the active ingredient of the pharmaceutical composition consists of activated CAR T cells as described herein. Pharmaceutically acceptable carriers for cell-based therapeutic formulations include saline and aqueous buffer solutions, Ringer's solution, and serum components, such as serum albumin, HDL, and LDL. Terms such as "excipient", "carrier", "pharmaceutically acceptable carrier" are used interchangeably herein.

[0151] In some embodiments, the pharmaceutical composition comprising activated CAR T cells as described herein can be a parenteral dosage form. Since the administration of parenteral dosage forms typically bypasses the patient's natural defenses against pollutants, the components other than the CAR T cells themselves are preferably sterile or can be sterilized before being applied to the patient. Examples of parenteral dosage forms include, but are not limited to, ready-to-use injection solutions, dry products that can be dissolved or suspended in a pharmaceutically acceptable injection vehicle at any time, i.e., suspensions and emulsions for injection. Any of these can be added to the activated CART cell preparation before administration.

[0152] Suitable vehicles that can be used to provide parenteral dosage forms of activated CAR T cells as disclosed herein are well known to those skilled in the art. Examples include, but are not limited to, saline solutions; glucose solutions; aqueous vehicles including, but not limited to, sodium chloride injection, Ringer's injection, dextrose injection, dextrose and sodium chloride injection, and lactated Ringer's injection; vehicles that are miscible with water, such as, but not limited to, ethanol, polyethylene glycol, and propylene glycol; and non-aqueous vehicles, such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.

[0153] dose

[0154] The term "unit dosage form" as used herein refers to a dosage suitable for one administration. For example, a unit dosage form can be an amount of therapeutic agent placed in a delivery device (e.g., a syringe or an intravenous drip bag). In one embodiment, the unit dosage form is administered in the form of a single administration. In another embodiment, more than one unit dosage form can be administered simultaneously.

[0155] In some embodiments, the activated CAR T cells described herein are administered as a monotherapy, i.e., not simultaneously administered to a subject with another treatment for the disorder.

[0156] The pharmaceutical composition comprising the T cells described herein can generally be administered at 10 4 to 10 9 cells / kg body weight, in some cases, 10 5 to 10 6 Cells / kg body weight, including all integer values ​​within these ranges. If desired, T cell compositions can also be administered multiple times at these doses. These cells can be administered using infusion techniques commonly known in immunotherapy (see, e.g., Rosenberg et al., New Eng. J. Med. [New England Journal of Medicine] 319: 1676, 1988).

[0157] In some aspects, it may be necessary to administer activated CAR T cells to a subject, then subsequently redraw blood (or perform apheresis), activate T cells therefrom as described herein, and reinfuse these activated and amplified T cells to the patient. This process can be performed several times every few weeks. In some aspects, T cells from 10cc to 400cc blood draws can be activated. In some aspects, T cells from 20cc, 30cc, 40cc, 50cc, 60cc, 70cc, 80cc, 90cc or 100cc blood draws are activated.

[0158] Administration may include, for example, intravenous (iv) injection or infusion. The compositions described herein may be administered to the patient via an artery, intratumor, intranodal or intramedullary. In some embodiments, the composition of T cells may be injected directly into a tumor, lymph node or site of infection. In one embodiment, the compositions described herein are administered into a body cavity or body fluid (e.g., ascites, pleural fluid, peritoneal fluid or cerebrospinal fluid).

[0159] In a specific exemplary aspect, the subject may undergo leukapheresis, wherein leukocytes are collected, enriched or depleted in vitro to select and / or separate cells of interest, e.g., T cells. These T cell isolates can be amplified by contact with artificial antigen presenting cells (aAPC) (e.g., aAPC expressing anti-CD28 and anti-CD3 CDR), and processed so that one or more CAR constructs of the present invention can be introduced, thereby producing CAR T cells. Subjects in need can then undergo standard treatment with high-dose chemotherapy, followed by peripheral blood stem cell transplantation. After or while transplanting, the subject can receive an infusion of amplified CAR T cells. In one embodiment, the amplified cells are administered before or after surgery.

[0160] In some embodiments, prior to administering one or more CAR T cells as described herein, the subject is subjected to lymphocyte clearance. In such embodiments, the lymphocyte clearance may include administering one or more of melphalan, cyclophosphamide, cyclophosphamide, and fludarabine.

[0161] The dosage of the above treatments that should be administered to a patient will vary depending on the exact nature of the condition being treated and the recipient of the treatment. Scaling of dosages for human administration can be performed according to art-recognized practices.

[0162] In some embodiments, a single treatment regimen is desired. In other embodiments, one or more subsequent doses or treatment regimens may be administered. For example, after a biweekly treatment for three months, the treatment may be repeated monthly for six months or a year or longer. In some embodiments, no additional treatment is administered after the initial treatment.

[0163] The dosage of the composition as described herein can be determined by a physician and adjusted as necessary to accommodate the observed therapeutic effect. With regard to the duration and frequency of treatment, a skilled clinician will typically monitor the subject to determine when treatment provides a therapeutic benefit and determine whether to administer further cells, stop treatment, resume treatment, or make other changes to the treatment regimen. The dosage should not be so large as to cause adverse side effects, such as cytokine release syndrome. Typically, the dosage will vary with the patient's age, condition, and sex, and can be determined by a person skilled in the art. In the event of any complication, the dosage can also be adjusted by an individual physician.

[0164] Combination therapy

[0165] The activated CAR T cells described herein can be used in combination with other known agents and therapies. In one embodiment, anti-CD19 therapy and anti-CD79b therapy are administered to the subject. In another embodiment, anti-BCMA therapy is further administered to the subject. As used herein, "combination" administration means delivering two (or more) different treatments to the subject during the subject's disease, for example, after the subject is diagnosed with the disorder and before the disorder is cured or eliminated or before the treatment stops treatment for other reasons. Two or more treatments are delivered. In some embodiments, when the delivery of the second treatment begins, the delivery of a treatment is still being carried out, so that there is an overlap in the treatment administration. This is sometimes referred to as "simultaneous" or "concurrent delivery" in this article. In other embodiments, the delivery of a treatment ends before the delivery of another treatment begins. In some embodiments of any one case, the treatment is more effective due to the combined administration. For example, the second treatment is more effective, for example, compared with the second treatment administered without the first treatment, less second treatments observe equivalent effects, or the second treatment alleviates symptoms to a greater extent, or observes a similar situation as the first treatment. In some embodiments, delivery results in a reduction in symptoms or other parameters associated with the disorder that is greater than observed in another treatment delivered without one treatment. The effects of the two treatments may be partially additive, fully additive, or greater than additive. The delivery may allow the effect of the first treatment delivered to be detected when the second treatment is delivered. The activated CAR T cells described herein and at least one additional therapeutic agent may be administered simultaneously, in the same or separate compositions, or sequentially. For sequential administration, the CAR-expressing cells described herein may be administered first, and additional agents may be administered a second time, or the order of administration may be reversed. CAR T therapy and / or other therapeutic agents, procedures, or methods may be administered during an active disorder, or during a remission period or during a disease with less activity. CAR T therapy may be administered before another treatment, simultaneously with the treatment, after treatment, or during remission of the disorder.

[0166] When administered in combination, activated CAR T cells and additional agents (e.g., second or third agents), or all, can be administered in an amount or dosage higher, lower or the same as the amount or dosage of each agent used alone (e.g., as a monotherapy). In certain embodiments, the amount or dosage of activated CAR T cells, additional agents (e.g., second or third agents) or all is lower than (e.g., at least 20%, at least 30%, at least 40% or at least 50%) the amount or dosage of each agent used alone. In other embodiments, the amount or dosage of activated CAR T cells, additional agents (e.g., second or third agents) or all resulting in the desired effect (e.g., cancer treatment) is lower than (e.g., at least 20%, at least 30%, at least 40% or at least 50%) the amount or dosage of each agent alone required to achieve the same therapeutic effect. In further embodiments, the activated CAR T cells described herein can be used in combination with surgery, chemotherapy, radiotherapy, mTOR pathway inhibitors, immunosuppressants (such as cyclosporine, azathioprine, methotrexate, mycophenolate mofetil and FK506), antibodies or other immunoablative agents (such as CAMPATH, anti-CD3 antibodies), or other antibody therapies, cytotoxins, fludarabine, rapamycin, mycophenolic acid, steroids, FR901228, cytokines or peptide vaccines in a treatment regimen as described in Izumoto et al., J. Neurosurg. [Journal of Neurosurgery] 108:963-971, 2008.

[0167] In one embodiment, activated CAR T cells described herein can be used in combination with checkpoint inhibitors. Exemplary checkpoint inhibitors include anti-PD-1 inhibitors (nivolumab, MK-3475, pembrolizumab, piridilimonab, AMP-224, AMP-514), anti-CTLA4 inhibitors (ipilimumab and tesimumab), anti-PDL1 inhibitors (atezumab, avelomab (Avelomab), MSB0010718C, MEDI4736 and MPDL3280A), and anti-TIM3 inhibitors.

[0168] In one embodiment, activated CAR T cells as described herein can be used in combination with chemotherapeutic agents.Exemplary chemotherapeutic agents include anthracyclines (e.g., doxorubicin (e.g., liposomal doxorubicin)), vinca alkaloids (e.g., vinblastine, vincristine, vindesine, vinorelbine), alkylating agents (e.g., cyclophosphamide, dacarbazine, melphalan, ifosfamide, temozolomide), immune cell antibodies (e.g., alemtuzumab, gemtuzumab, rituximab, tositumomab), antimetabolites (including, for example, folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors (e.g., fludarabine)), mTOR inhibitors, TNFR glucocorticoid-induced TNFR-related proteins (GITR) agonists, proteasome inhibitors (e.g., aclarubicin A, gliotoxin or bortezomib), immunomodulators (such as thalidomide or thalidomide derivatives (e.g., lenalidomide)). General chemotherapy drugs considered for combination therapy include anastrozole Bicalutamide Bleomycin sulfate Busulfan Busulfan Injection Capecitabine N4-pentyloxycarbonyl-5-deoxy-5-fluorocytidine, carboplatin Carmustine Chlorambucil Cisplatin Cladribine Cyclophosphamide ( or ), cytosine arabinoside, cytosine arabinoside Cytarabine liposome injection Dacarbazine Actinomycin (Actinomycin D, Cosmegan), daunorubicin hydrochloride Daunorubicin citrate liposome injection Dexamethasone, docetaxel Doxorubicin Hydrochloride Etoposide Fludarabine phosphate 5-Fluorouracil Flutamide Tezacitabine, gemcitabine (difluorodeoxycytidine), hydroxyurea Idaunorubicin Ifosfamide Irinotecan L-Asparaginase Calcium leucovorin, melphalan 6-Mercaptopurine Methotrexate Mitoxantrone Gemtuzumab, paclitaxel Phoenix (Yttrium90 / MX-DTPA), Pentostatin, Carmustine Polyphenylpropanone 20 Implantable Tablets Tamoxifen citrate Teniposide 6-thioguanine, thiotepa, tirapazamine Topotecan Hydrochloride for Injection Vinblastine Vincristine Vinorelbine Exemplary alkylating agents include, but are not limited to, nitrogen mustards, ethyleneimine derivatives, alkyl sulfonates, nitrosoureas, and triazenes: Aminouracil Uracil nitrogen ), Nitrogen mustard hydrochloride Cyclophosphamide ( Revimmune TM ), ifosfamide Melphalan Chlorambucil Pipobrom Triethylene melamine Triethylenethiophosphamide, temozolomide Thiotepa Busulfan Carmustine Lomustine Streptozotocin and dacarbazine Additional exemplary alkylating agents include, but are not limited to, oxaliplatin Temozolomide ( and ); Dactinomycin (also known as actinomycin-D, ); Melphalan (also known as L-PAM, L-hemolysin, and phenylalanine mustard, ); Hexamethylmelamine (also known as hexamethylmelamine (HMM), ); Carmustine Bendamustine Busulfan and ); Carboplatin Lomustine (also known as CCNU, ); cisplatin (also known as CDDP, and -AQ); Chlorambucil Cyclophosphamide ( and ); Dacarbazine (also known as DTIC, DIC, and imidazole carboxamide, ); Hexamethylmelamine (also known as hexamethylmelamine (HMM), ); ifosfamide Prednumustine; Procarbazine Dichloromethyldiethylamine (also known as nitrogen mustard, erucic acid and methylchloroethylamine hydrochloride, ); Streptozotocin Thiotepa (also known as thiophosphoramide, TESPA and TSPA, ); Cyclophosphamide Bendamustine hydrochloride Exemplary mTOR inhibitors include, for example, temsirolimus; ridaforolimus (formally known as deferolimus, (1R, 2R, 45)-4-[(2R)-2[(1R, 95, 125, 15R, 16E, 18R, 19R, 21R, 235, 24E, 26E, 28Z, 305, 325, 35R)-1,18-dihydroxy-19 ,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxa-11,36-dioxa-4-azatricyclo[30.3.1.04'9]triacontac-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphite, also known as AP23573 and MK8669, and described in PCT Publication No. WO 03 / 064383); everolimus ( or RADOOl); Rapamycin (AY22989, ); semamod (CAS164301-51-3); temsirolimus, (5-{2,4-bis[(35,)-3-methylmorpholin-4-yl]pyrido[2,3-(i]pyrimidin-7-yl}-2-methoxyphenyl)methanol (AZD8055); 2-amino-8-[iraw5,-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido[2,3-(i]pyrimidin-7(8H)-one (PF04691502, CAS 1013101-36-4); and N2-[1,4-dioxo-4-[[4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl]methoxy]butyl]-L-arginyl glycidyl-La-aspartyl L-serine, inner salt (SF1126, CAS 936487-67-1), and XL765. Exemplary immunomodulators include, for example, avozumab (available from Pegfilgrastim Lenalidomide (CC-5013, ); thalidomide actimid (CC4047); and IRX-2 (a mixture of human cytokines including interleukin 1, interleukin 2, and interferon gamma, CAS 951209-71-5, available from IRX Therapeutics). Exemplary anthracyclines include, for example, doxorubicin ( and ); Bleomycin Daunorubicin (doxorubicin hydrochloride, daunomycin and ruvidonomycin hydrochloride, ); daunorubicin liposomes (daunorubicin citrate liposomes, ); Mitoxantrone (DHAD, ); Ellence TM ); Idaunorubicin ( Idamycin ); Mitomycin C geldanamycin; herbimycin; ravidomycin; and desacetyl ravamicin. Exemplary vinca alkaloids include, for example, vinorelbine tartrate Vincristine Vindesine ); Vinblastine (also known as vinblastine sulfate, vinblastine, and VLB, and ); and vinorelbine Exemplary proteasome inhibitors include bortezomib Carfilzomib (PX-171-007, (5)-4-methyl-N-((5)-1-(((5)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((5,)-2-(2-morpholinoacetylamino)-4-phenylbutanamido)-pentanamide); marizomib (NPT0 052); ixazomib citrate (MLN-9708); delanzomib (CEP-18770); and O-methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(llS')-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-l-(phenylmethyl)ethyl]-L-serinamide (ONX-0912).

[0169] The chemotherapeutic agents used can be readily identified by one skilled in the art (e.g., see Physicians' Cancer Chemotherapy Drug Manual 2014, Edward Chu, Vincent T. DeVita Jr., Jones & Bartlett Learning; Principles of Cancer Therapy, Harrison, Principles of Internal Medicine, Chapter 85, 18th ed.; Therapeutic Targeting of Cancer Cells: Era of Molecularly Targeted Agents and Cancer Pharmacology, Abeloff, Clinical Oncology, Chapters 28-29, 2013 Elsevier; and Fischer DS (ed.): The Cancer Chemotherapy Handbook, 4th ed. St. Louis, Mosby-Year Book, 2003).

[0170] In one embodiment, the activated CAR T cells described herein are administered to a subject in combination with a molecule that reduces the activity and / or level of a molecule that targets GITR and / or modulates GITR function, a molecule that reduces the Treg cell population, an mTOR inhibitor, a GITR agonist, a kinase inhibitor, a non-receptor tyrosine kinase inhibitor, a CDK4 inhibitor, and / or a BTK inhibitor.

[0171] effect

[0172] The efficacy of activated CAR T cells, such as efficacy in the treatment of conditions described herein, or the efficacy of inducing responses as described herein (e.g., reduction of cancer cells), can be determined by skilled clinicians. However, treatment as used herein is considered to be a term of "effective treatment", meaning that one or more signs or symptoms of the conditions described herein are changed in a beneficial manner, other clinically acceptable symptoms are improved, or even alleviated, or the desired response is induced after treatment according to the methods described herein, for example, at least 10%. For example, efficacy can be assessed by measuring markers, indicators, symptoms and / or incidence rates of conditions treated according to the methods described herein, or any other appropriate measurable parameters. Treatment according to the methods described herein can reduce the level of markers or symptoms of the condition, for example, by reducing at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% or more.

[0173] Efficacy can also be measured by failure of an individual to deteriorate (ie, cessation of progression of the disease) as assessed by hospitalization, or the need for medical intervention. Methods for measuring these indicators are known to those of skill in the art and / or described herein.

[0174] Treatment includes any treatment of a disease in an individual or animal (some non-limiting examples include humans or animals) and includes: (1) inhibiting the disease, e.g., preventing worsening of symptoms (e.g., pain or inflammation); or (2) alleviating the severity of the disease, e.g., causing regression of symptoms. An effective amount for treating a disease refers to an amount that is sufficient to result in effective treatment of the disease as defined herein when administered to a subject in need thereof. The efficacy of an agent can be determined by assessing physical indicators of the condition or desired response. It is within the capabilities of those skilled in the art to monitor the efficacy of administration and / or treatment by measuring any one such parameter or any combination of parameters. The efficacy of a given method can be evaluated in an animal model of a condition described herein, e.g., treating lymphoma as described herein. When an experimental animal model is used, the efficacy of the treatment is demonstrated when a statistically significant marker change is observed.

[0175] All patents and other publications; including references, issued patents, published patent applications, and co-pending patent applications; cited throughout this application are expressly incorporated herein by reference for the purpose of describing and disclosing, for example, the methods described in these publications, which may be used in conjunction with the techniques described herein. These publications are provided only for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate disclosure by reason of prior invention or for any other reason. All statements as to dates or representations as to the contents of these documents are based on the information available to the applicants and do not constitute any admission as to the correctness of the dates or contents of these documents.

[0176] The description of the embodiments of the present disclosure is not intended to be exhaustive or intended to limit the present invention to the precise form disclosed. Although the specific embodiments and examples of the present disclosure are described herein for illustrative purposes, as will be appreciated by those skilled in the relevant art, various equivalent modifications can be made within the scope of the present disclosure. For example, although the method steps or functions are presented in a given order, alternative embodiments can perform functions in different orders, or can perform functions substantially simultaneously. The teachings of the present disclosure provided herein can be appropriately applied to other programs or methods. The different embodiments described herein can be combined to provide further embodiments. If necessary, the various aspects of the present disclosure can be modified to provide further embodiments of the present disclosure using the compositions, functions and concepts of the above-mentioned references and applications. In addition, due to biological functional equivalence considerations, some changes can be made in the protein structure without affecting the biological or chemical effects of the species or quantity. These and other changes can be made to the present disclosure according to the specific embodiments. All such modifications are intended to be included within the scope of the appended claims.

[0177] The specific elements of any of the foregoing embodiments may be combined or replace the elements in other embodiments. In addition, although the advantages associated with certain embodiments of the present disclosure have been described in the context of these embodiments, other embodiments may also exhibit such advantages, and not all embodiments must exhibit these advantages to fall within the scope of the present disclosure.

[0178] The technology described herein is further illustrated by the following examples, which should in no way be construed as further limiting

[0179] Examples

[0180] Example 1

[0181] We have designed CARs that target CD79b, part of the B cell receptor (BCR) complex. With this approach, we have increased treatment options for lymphoma patients (e.g., lymphoma patients with relapsed CD19-negative disease after CD19 CAR therapy). We have also designed bispecific CARs that target both CD79b and CD19.

[0182] Materials and methods

[0183] We generated CAR constructs using scFv-based anti-CD79b fused to 4-1BB and CD3ζ via the CD8 hinge and transmembrane domains. Human primary T cells were lentivirally transduced with CD79b or CD19 CAR. Cytotoxicity, T cell activation, and cytokine production were evaluated against the MCL cell line Jeko-1. In addition, the cytotoxic effects of CD79b CAR compared with CD19 CAR were evaluated in xenograft experiments in Jeko-1 tumor-bearing mice as well as in mice bearing MCL PDX tumors.

[0184] result

[0185] Figure 1 The results of characterization of the cell surface expression of CD79b and CD19 and CD79a, CD37, BCMA, TACI, Fas, CD38 and CD138 of the MCL cell line Jeko-1 are shown. The lentiviral constructs expressing CD19 (H / L) CAR, CD79b (L / H) CAR and CD79b (H / L) CAR (see, e.g., Figure 2 ) effectively transduced human primary T cells ( Figure 3 ). Figure 4 Growth curves of untransduced cells and cells transduced with CD79b(L / H)CAR and CD79b(H / L)CAR are shown. Figure 5 Shown are activation levels of Jurkat NFAT luc reporter cells transduced with CD19 or CD79b CAR after overnight incubation with the indicated target cells expressing CD19 or CD79b (n=3).

[0186] In vitro studies have shown that CAR-transduced T cells incubated overnight with Jeko-1 cells expressing luciferase have a cytotoxic effect ( Figure 6 ). CD19(H / L)CAR and CD79b(L / H)CAR showed relatively high cytotoxicity levels. After overnight incubation with Jeko-1 cells (1:1 ratio), the levels of effector cytokines produced by CD19, CD79b(L / H), and CD79b(H / L)CAR were shown in Figure 2. Figure 7 shown.

[0187] The CAR T cells were then tested in two in vivo animal models. Fig. 8A A timeline of a mouse xenograft model is shown, where mice received 1e6 Jeko-1-Luc+ cells followed by 2e6 CAR T cells injected intravenously 7 days later. Cytotoxic effects of CAR T cells (CD79b(L / H) and CD19 CAR) compared to untransduced cells as measured by FLUX. Figure 8B The number of CAR T cells present in the blood 14 days after injection using TrueCount beads is shown in Figure 8C shown. Fig. 9A A timeline of a mouse xenograft model is shown, where mice received 1e6 MCL PDX cells and 3e6 CAR T cells 39 days after tumor injection. Cytotoxic effects of CAR T cells on PDX tumor cells as measured by FLUX are shown. Fig. 9B shown.

[0188] Fig.10 The bispecific CAR was shown to be activated by cells expressing both CD19 and CD79b (n=3).

[0189] in conclusion

[0190] CD79b CAR shows high tumor clearance rate, cytokine production, expansion and activation after repeated antigen stimulation in in vitro assays. Evaluating tumor clearance rate in a xenograft model of MCL shows that in multiple healthy T cell donors, tumors are completely removed with CD79b CAR (comparable to CD19 CAR). In addition, it is shown that bispecific CAR is activated by cells expressing both CD19 and CD79b.

[0191] Example 2

[0192] The sequences of two CAR polypeptides of the present invention directed against CD79b are provided and described as follows.

[0193] pMGH73 includes the following domains: CD8L, anti-CD79b L / H (separated by a linker), CD8 TM and hinge, 4-1BB, and CD3ζ, the sequences of which are shown below:

[0194] MALPVTALLLPLALLLHAARPDIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSIQPEDFATYYCQQSNEDPLTFGQGTKVEIKRGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO:1).

[0195] The sequence of the CD8 leader is: MALPVTALLLPLALLLHAARP (SEQ ID NO:3).

[0196] The sequence of the light chain is: DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSIQPEDFATYYCQQSNEDPLTFGQGTKVEIKR (SEQ ID NO:4).

[0197] The sequence of the linker is:GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:5).

[0198] The sequence of the heavy chain is: EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS (SEQ ID NO:6).

[0199] The sequence of the CD8 transmembrane and hinge domain is: TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYC (SEQ ID NO: 7).

[0200] The sequence of 4-1BB ICD is: KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL (SEQ ID NO: 8).

[0201] The sequence of CD3ζICD is: RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 9).

[0202] pMGH74 includes the following domains: CD8L, anti-CD79b H / L (separated by a linker), CD8 TM and hinge, 4-1BB, and CD3ζ, the sequences of which are shown below

[0203] MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIR LDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQLTQSPSSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSIQPEDFATY YCQQSNEDPLTFGQGTKVEIKRTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFP EEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO:2)

[0204] The sequence of the CD8 leader sequence is: MALPVTALLLPLALLLHAARP (SEQ ID NO: 3).

[0205] The sequence of the heavy chain is: EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS (SEQ ID NO: 6).

[0206] The sequence of the linker is: GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 5).

[0207] The sequence of the light chain is: DIQLTQSPSSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSIQPEDFATYYCQQSNEDPLTFGQGTKVEIKR (SEQID NO: 4).

[0208] The sequence of the CD8 transmembrane and hinge domain is: TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYC (SEQ ID NO: 7).

[0209] The sequence of 4-1BB ICD is: KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL (SEQ ID NO: 8).

[0210] The sequence of CD3ζICD is: RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 9).

[0211] Example 3

[0212] The sequences of two CAR polypeptides of the present invention directed against CD79b and CD19 are provided and described as follows.

[0213] The first CAR includes the following domains: CD8L, anti-CD79b L / H (L and H are separated by a linker), a linker, an anti-CD19 scFv (including a glycine-rich linker between the heavy chain and the light chain), a CD8 TM and hinge, 4-1BB, and CD3ζ, the sequence of which is shown below:

[0214] (SEQ ID NO: 10).

[0215] The sequence of the CD8 leader sequence is: MALPVTALLLPLALLLHAARP (SEQ ID NO: 3).

[0216] The sequence of anti-CD79b(L / H) scFv is: DIQLTQSPSSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSIQPEDFATYYCQQSNEDPLTFGQGTKVEIKRGGGG SGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS(SEQ ID NO:12).

[0217] The sequence of the linker is: GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 5).

[0218] The sequence of the anti-CD19 scFv (including the glycine-rich linker separating the heavy and light chains) is EIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKGGGGSGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYQSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSS (SEQ ID NO: 13).

[0219] The sequence of the CD8 transmembrane and hinge domain is: TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYC (SEQ ID NO: 7).

[0220] The sequence of 4-1BB ICD is: KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL (SEQ ID NO: 8).

[0221] The sequence of CD3ζICD is RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 9).

[0222] The second CAR includes the following domains: CD8L, anti-CD19 scFv (including a glycine-rich linker separating the heavy and light chains), a linker, anti-CD79b L / H (L and H are separated by a linker), CD8 TM and hinge, 4-1BB, and CD3ζ, and its sequence is shown below:

[0223] MALPVTALLLPLALLLHAARPEIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKGGGGSGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYQSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSIQPEDFATYYCQQSNEDPLTFGQGTKVEIKRGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO:11).

[0224] The sequence of the CD8 leader sequence is: MALPVTALLLPLALLLHAARP (SEQ ID NO:3).

[0225] The sequence of the anti-CD19 scFv (including the glycine-rich linker separating the heavy and light chains) is EIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLHSGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKGGGGSGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGKGLEWIGVIWGSETTYYQSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSS (SEQ ID NO: 13).

[0226] The sequence of the linker is: GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 5).

[0227] The sequence of anti-CD79b(L / H) scFv is: DIQLTQSPSSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSIQPEDFATYYCQQSNEDPLTFGQGTKVEIKRGGGG SGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS(SEQ ID NO:12).

[0228] The sequence of the CD8 transmembrane and hinge domain is: TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYC (SEQ ID NO: 7).

[0229] The sequence of 4-1BB ICD is: KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL (SEQ ID NO: 8).

[0230] The sequence of CD3ζICD is RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 9).

[0231] Other embodiments are within the scope of the following numbered paragraphs.

[0232] 1. A chimeric antigen receptor (CAR) polypeptide comprising an extracellular domain comprising a sequence that specifically binds to CD79b.

[0233] 2. The CAR polypeptide as described in paragraph 1, wherein the sequence that specifically binds to CD79b comprises an antigen binding region of an antibody against CD79b.

[0234] 3. The CAR polypeptide as described in paragraph 1 or 2, wherein the sequence that specifically binds to CD79b comprises a single-chain antibody (scFv) against CD79b.

[0235] 4. The CAR polypeptide of paragraph 3, wherein the scFv comprises a light chain and a heavy chain.

[0236] 5. The CAR polypeptide of paragraph 4, wherein the light chain is at the N-terminus of the heavy chain.

[0237] 6. The CAR polypeptide of paragraph 4, wherein the heavy chain is at the N-terminus of the light chain.

[0238] 7. The CAR polypeptide of any one of paragraphs 1 to 6, further comprising one, more or all of a hinge domain, a transmembrane domain, a co-stimulatory domain, and a signaling domain.

[0239] 8. The CAR polypeptide of paragraph 7, comprising all of the hinge, transmembrane domain, co-stimulatory domain, and signaling domain.

[0240] 9. The CAR polypeptide of paragraph 7 or 8, wherein the hinge and transmembrane domain are CD8 hinge and transmembrane domain.

[0241] 10. The CAR polypeptide of any one of paragraphs 7 to 9, wherein the co-stimulatory domain is a 4-1BB co-stimulatory domain.

[0242] 11. The CAR polypeptide of any of paragraphs 7 to 10, wherein the signaling domain is a CD3 zeta signaling domain.

[0243] 12. The CAR polypeptide of any one of paragraphs 1 to 11, comprising an anti-CD79b scFv, a CD8 hinge and transmembrane domain, a 4-1BB co-stimulatory domain, and a CD3ζ signaling domain.

[0244] 13. The CAR polypeptide of any one of paragraphs 1 to 12, wherein the extracellular domain further comprises a sequence that specifically binds to CD19.

[0245] 14. The CAR polypeptide of paragraph 13, wherein the sequence that specifically binds to CD19 comprises an antigen binding region of an antibody against CD19.

[0246] 15. The CAR polypeptide of paragraph 13 or 14, wherein the sequence that specifically binds to CD19 comprises a single-chain antibody (scFv) against CD19.

[0247] 16. The CAR polypeptide of paragraph 15, wherein the scFv comprises a light chain and a heavy chain.

[0248] 17. The CAR polypeptide of paragraph 16, wherein the light chain is at the N-terminus of the heavy chain.

[0249] 18. The CAR polypeptide of paragraph 16, wherein the heavy chain is at the N-terminus of the light chain.

[0250] 19. The CAR polypeptide of any one of paragraphs 13 to 18, wherein the sequence that binds to CD79b is at the N-terminus of the sequence that binds to CD19.

[0251] 20. The CAR polypeptide of any one of paragraphs 13 to 18, wherein the sequence that binds to CD19 is at the N-terminus of the sequence that binds to CD79b.

[0252] 21. The CAR polypeptide of any one of paragraphs 1 to 20, comprising the sequence of SEQ ID NO: 1, 2, 10 or 11 or a variant thereof, wherein the sequence optionally omits the CD8 leader sequence of SEQ ID NO: 3.

[0253] 22. The CAR polypeptide of any one of paragraphs 1 to 21, comprising the CD8 leader sequence of SEQ ID NO: 3 or a variant thereof.

[0254] 23. The CAR polypeptide of any one of paragraphs 1 to 22, comprising the anti-CD79b light chain sequence of SEQ ID NO: 4 or a variant thereof.

[0255] 24. The CAR polypeptide of any one of paragraphs 1 to 23, comprising the anti-CD79b heavy chain sequence of SEQ ID NO: 6 or a variant thereof.

[0256] 25. The CAR polypeptide of any one of paragraphs 1 to 24, comprising a linker sequence of SEQ ID NO: 5 or a variant thereof.

[0257] 26. The CAR polypeptide of any one of paragraphs 1 to 25, comprising the CD8 transmembrane and hinge sequences of SEQ ID NO: 7 or a variant thereof.

[0258] 27. The CAR polypeptide of any one of paragraphs 1 to 26, comprising the 4-1BBICD sequence of SEQ ID NO: 8 or a variant thereof.

[0259] 28. The CAR polypeptide of any one of paragraphs 1 to 27, comprising the CD3ζICD sequence of SEQ ID NO: 9 or a variant thereof.

[0260] 29. The CAR polypeptide of any one of paragraphs 13 to 20, comprising the anti-CD19 scFv sequence of SEQ ID NO: 13 or a variant thereof.

[0261] 30. A nucleic acid molecule comprising a sequence encoding the CAR polypeptide of any one of paragraphs 1 to 29.

[0262] 31. A vector comprising the nucleic acid molecule of paragraph 30.

[0263] 32. A cell comprising the CAR polypeptide of any one of paragraphs 1 to 29, the nucleic acid molecule of paragraph 30, or the vector of paragraph 31.

[0264] 33. The cell of paragraph 32, wherein the cell is a primary human T cell.

[0265] 34. A pharmaceutical composition comprising the CAR polypeptide of any one of paragraphs 1 to 29, the nucleic acid molecule of paragraph 30, the vector of paragraph 31, or the cell of paragraph 32 or 33.

[0266] 35. A method of treating a subject having or at risk of developing cancer, the method comprising administering to the subject the pharmaceutical composition of paragraph 34.

[0267] 36. The method of paragraph 35, wherein the cancer is lymphoma.

[0268] 37. The method of paragraph 36, wherein the lymphoma is non-Hodgkin's lymphoma.

[0269] 38. The method of paragraph 37, wherein the non-Hodgkin lymphoma is selected from the group consisting of mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

[0270] 39. A method of treating a subject whose CD19-negative lymphoma has relapsed after receiving CD19 CAR therapy, the method comprising administering to the subject a pharmaceutical composition as described in paragraph 34.

[0271] 40. A method for preparing a CAR T cell expressing a CD79b-specific CAR or a CD79b and CD19-specific CAR, the method comprising introducing the nucleic acid molecule as described in paragraph 30 or the vector as described in paragraph 31 into a T cell.

[0272] 41. The method of paragraph 40, wherein the T cell is a primary human T cell. Sequence Listing <110> The General Hospital Corporation University of Southern Denmark <120> T cells expressing chimeric antigen receptors <130> 51295-010WO3 <150> US 62 / 627,514 <151> 2018-02-07 <150> US 62 / 516,234 <151> 2017-06-07 <160> 13 <170> PatentIn Version 3.5 <210> 1 <211> 493 <212> PRT <213> Artificial sequence <220> <223> Synthetic constructs <400> 1 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu 20 25 30 Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln 35 40 45 Ser Val Asp Tyr Glu Gly Asp Ser Phe Leu Asn Trp Tyr Gln Gln Lys 50 55 60 Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu 65 70 75 80 Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe 85 90 95 Thr Leu Thr Ile Ser Ser Ile Gln Pro Glu Asp Phe Ala Thr Tyr Tyr 100 105 110 Cys Gln Gln Ser Asn Glu Asp Pro Leu Thr Phe Gly Gln Gly Thr Lys 115 120 125 Val Glu Ile Lys Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 130 135 140 Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser 145 150 155 160 Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala 165 170 175 Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Trp Ile Glu Trp Val Arg Gln 180 185 190 Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Leu Pro Gly Gly 195 200 205 Gly Asp Thr Asn Tyr Asn Glu Ile Phe Lys Gly Arg Ala Thr Phe Ser 210 215 220 Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg 225 230 235 240 Ala Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Arg Val Pro Ile Arg 245 250 255 Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Thr Thr 260 265 270 Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln 275 280 285 Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala 290 295 300 Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala 305 310 315 320 Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr 325 330 335 Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln 340 345 350 Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser 355 360 365 Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys 370 375 380 Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln 385 390 395 400 Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu 405 410 415 Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg 420 425 430 Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met 435 440 445 Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly 450 455 460 Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp 465 470 475 480 Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 485 490 <210> 2 <211> 493 <212> PRT <213> artificial sequence <220> <223> composite structure <400> 2 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu 20 25 30 Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr 35 40 45 Thr Phe Ser Ser Tyr Trp Ile Glu Trp Val Arg Gln Ala Pro Gly Lys 50 55 60 Gly Leu Glu Trp Ile Gly Glu Ile Leu Pro Gly Gly Gly Asp Thr Asn 65 70 75 80 Tyr Asn Glu Ile Phe Lys Gly Arg Ala Thr Phe Ser Ala Asp Thr Ser 85 90 95 Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr 100 105 110 Ala Val Tyr Tyr Cys Thr Arg Arg Val Pro Ile Arg Leu Asp Tyr Trp 115 120 125 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly 130 135 140 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile 145 150 155 160 Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg 165 170 175 Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Asp Tyr Glu Gly Asp 180 185 190 Ser Phe Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu 195 200 205 Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Val Pro Ser Arg Phe 210 215 220 Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Ile 225 230 235 240 Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Glu Asp 245 250 255 Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Thr 260 265 270 Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln 275 280 285 Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala 290 295 300 Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala 305 310 315 320 Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr 325 330 335 Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln 340 345 350 Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser 355 360 365 Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys 370 375 380 Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln 385 390 395 400 Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu 405 410 415 Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg 420 425 430 Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met 435 440 445 Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly 450 455 460 Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp 465 470 475 480 Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 485 490 <210> 3 <211> twenty one <212> PRT <213> Artificial sequence <220> <223> Synthetic constructs <400> 3 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro 20 <210> 4 <211> 112 <212> PRT <213> Artificial sequence <220> <223> Synthetic constructs <400> 4 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Asp Tyr Glu 20 25 30 Gly Asp Ser Phe Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro 35 40 45 Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Val Pro Ser 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Ser Ile Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 85 90 95 Glu Asp Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 100 105 110 <210> 5 <211> 20 <212> PRT <213> Artificial sequence <220> <223> Synthetic constructs <400> 5 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1 5 10 15 Gly Gly Gly Ser 20 <210> 6 <211> 117 <212> PRT <213> Artificial sequence <220> <223> Synthetic constructs <400> 6 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Ser Ser Tyr 20 25 30 Trp Ile Glu Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Leu Pro Gly Gly Gly Asp Thr Asn Tyr Asn Glu Ile Phe 50 55 60 Lys Gly Arg Ala Thr Phe Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Arg Val Pro Ile Arg Leu Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 7 <211> 69 <212> PRT <213> artificial sequence <220> <223> Synthesize construction <400> 7 Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala 1 5 10 15 Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly 20 25 30 Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile 35 40 45 Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val 50 55 60 Ile Thr Leu Tyr Cys 65 <210> 8 <211> 42 <212> PRT <213> Artificial sequence <220> <223> Synthetic constructs <400> 8 Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met 1 5 10 15 Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe 20 25 30 Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu 35 40 <210> 9 <211> 112 <212> PRT <213> Artificial sequence <220> <223> Synthetic constructs <400> 9 Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly 1 5 10 15 Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr 20 25 30 Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys 35 40 45 Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys 50 55 60 Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg 65 70 75 80 Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala 85 90 95 Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 100 105 110 <210> 10 <211> 760 <212> PRT <213> artificial sequence <220> <223> Synthesize construction <400> 10 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu 20 25 30 Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln 35 40 45 Ser Val Asp Tyr Glu Gly Asp Ser Phe Leu Asn Trp Tyr Gln Gln Lys 50 55 60 Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu 65 70 75 80 Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe 85 90 95 Thr Leu Thr Ile Ser Ser Ile Gln Pro Glu Asp Phe Ala Thr Tyr Tyr 100 105 110 Cys Gln Gln Ser Asn Glu Asp Pro Leu Thr Phe Gly Gln Gly Thr Lys 115 120 125 Val Glu Ile Lys Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 130 135 140 Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser 145 150 155 160 Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala 165 170 175 Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Trp Ile Glu Trp Val Arg Gln 180 185 190 Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Leu Pro Gly Gly 195 200 205 Gly Asp Thr Asn Tyr Asn Glu Ile Phe Lys Gly Arg Ala Thr Phe Ser 210 215 220 Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg 225 230 235 240 Ala Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Arg Val Pro Ile Arg 245 250 255 Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 260 265 270 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 275 280 285 Gly Ser Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser 290 295 300 Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asp Ile Ser 305 310 315 320 Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu 325 330 335 Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Ile Pro Ala Arg Phe 340 345 350 Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu 355 360 365 Gln Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Gly Asn Thr Leu 370 375 380 Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly 385 390 395 400 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 405 410 415 Ser Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser 420 425 430 Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp 435 440 445 Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 450 455 460 Ile Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Gln Ser Ser Leu 465 470 475 480 Lys Ser Arg Val Thr Ile Ser Lys Asp Asn Ser Lys Asn Gln Val Ser 485 490 495 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 500 505 510 Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly 515 520 525 Gln Gly Thr Leu Val Thr Val Ser Ser Thr Thr Thr Pro Ala Pro Arg 530 535 540 Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg 545 550 555 560 Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly 565 570 575 Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr 580 585 590 Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg 595 600 605 Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro 610 615 620 Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu 625 630 635 640 Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala 645 650 655 Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu 660 665 670 Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly 675 680 685 Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu 690 695 700 Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser 705 710 715 720 Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly 725 730 735 Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu 740 745 750 His Met Gln Ala Leu Pro Pro Arg 755 760 <210> 11 <211> 760 <212> PRT <213> artificial sequence <220> <223> Synthesize construction <400> 11 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu 20 25 30 Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln 35 40 45 Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala 50 55 60 Pro Arg Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Ile Pro 65 70 75 80 Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile 85 90 95 Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Gly 100 105 110 Asn Thr Leu Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 115 120 125 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 130 135 140 Gly Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val 145 150 155 160 Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser 165 170 175 Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly 180 185 190 Leu Glu Trp Ile Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Gln 195 200 205 Ser Ser Leu Lys Ser Arg Val Thr Ile Ser Lys Asp Asn Ser Lys Asn 210 215 220 Gln Val Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val 225 230 235 240 Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp 245 250 255 Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly 260 265 270 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 275 280 285 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 290 295 300 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Asp Tyr Glu 305 310 315 320 Gly Asp Ser Phe Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro 325 330 335 Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Val Pro Ser 340 345 350 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 355 360 365 Ser Ile Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 370 375 380 Glu Asp Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 385 390 395 400 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 405 410 415 Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 420 425 430 Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr 435 440 445 Phe Ser Ser Tyr Trp Ile Glu Trp Val Arg Gln Ala Pro Gly Lys Gly 450 455 460 Leu Glu Trp Ile Gly Glu Ile Leu Pro Gly Gly Gly Asp Thr Asn Tyr 465 470 475 480 Asn Glu Ile Phe Lys Gly Arg Ala Thr Phe Ser Ala Asp Thr Ser Lys 485 490 495 Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala 500 505 510 Val Tyr Tyr Cys Thr Arg Arg Val Pro Ile Arg Leu Asp Tyr Trp Gly 515 520 525 Gln Gly Thr Leu Val Thr Val Ser Ser Thr Thr Thr Pro Ala Pro Arg 530 535 540 Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg 545 550 555 560 Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly 565 570 575 Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr 580 585 590 Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg 595 600 605 Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro 610 615 620 Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu 625 630 635 640 Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala 645 650 655 Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu 660 665 670 Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly 675 680 685 Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu 690 695 700 Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser 705 710 715 720 Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly 725 730 735 Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu 740 745 750 His Met Gln Ala Leu Pro Pro Arg 755 760 <210> 12 <211> 249 <212> PRT <213> Artificial Sequence <220> <223> Synthetic construct <400> 12 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Asp Tyr Glu 20 25 30 Gly Asp Ser Phe Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro 35 40 45 Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Val Pro Ser 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Ser Ile Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 85 90 95 Glu Asp Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 100 105 110 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 115 120 125 Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 130 135 140 Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr 145 150 155 160 Phe Ser Ser Tyr Trp Ile Glu Trp Val Arg Gln Ala Pro Gly Lys Gly 165 170 175 Leu Glu Trp Ile Gly Glu Ile Leu Pro Gly Gly Gly Asp Thr Asn Tyr 180 185 190 Asn Glu Ile Phe Lys Gly Arg Ala Thr Phe Ser Ala Asp Thr Ser Lys 195 200 205 Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala 210 215 220 Val Tyr Tyr Cys Thr Arg Arg Val Pro Ile Arg Leu Asp Tyr Trp Gly 225 230 235 240 Gln Gly Thr Leu Val Thr Val Ser Ser 245 <210> 13 <211> 247 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 13 Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr His Thr Ser Arg Leu His Ser Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly Gly Ser 100 105 110 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln 115 120 125 Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr 130 135 140 Leu Ser Leu Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly 145 150 155 160 Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly 165 170 175 Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Gln Ser Ser Leu Lys Ser 180 185 190 Arg Val Thr Ile Ser Lys Asp Asn Ser Lys Asn Gln Val Ser Leu Lys 195 200 205 Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Lys 210 215 220 His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly 225 230 235 240 Thr Leu Val Thr Val Be Be 245

Claims

1. A chimeric antigen receptor (CAR) polypeptide, which is specific for CD79b or specific for CD79b and CD19 and is shown in SEQ ID NO: 1, 2, 10 or 11.

2. A nucleic acid molecule encoding the CAR polypeptide as described in claim 1.

3. A vector comprising the nucleic acid molecule according to claim 2.

4. A cell comprising the nucleic acid molecule according to claim 2 or the vector according to claim 3.

5. The cell of claim 4, wherein the cell is a primary human T cell.

6. A pharmaceutical composition comprising the nucleic acid molecule of claim 2, the vector of claim 3 or the cell of claim 4 or 5.

7. Use of the CAR polypeptide as described in claim 1, the nucleic acid molecule as described in claim 2, the vector as described in claim 3, the cell as described in claim 4 or 5, or the pharmaceutical composition as described in claim 6 for preparing a drug for treating subjects suffering from mantle cell lymphoma (MCL) or at risk of developing mantle cell lymphoma (MCL).

8. Use of the CAR polypeptide as claimed in claim 1, the nucleic acid molecule as claimed in claim 2, the vector as claimed in claim 3, the cell as claimed in claim 4 or 5, or the pharmaceutical composition as claimed in claim 6 for preparing a drug for treating a subject with relapsed CD19-negative mantle cell lymphoma (MCL) after receiving CD19 CAR therapy.

9. A method for preparing a CAR T cell expressing a CD79b-specific CAR or a CD79b- and CD19-specific CAR, the method comprising introducing the nucleic acid molecule of claim 2 or the vector of claim 3.

10. The method of claim 9, wherein the T cells are human primary T cells.